annual reportthreeyear briefworldwide change dollar million share figure sale customer net earning cash dividend pay shareholder equity percent return average shareholder equity share net earning basic diluted cash dividend pay shareholder equity market price yearend close average share outstanding million basic diluted number employee thousand net earning earning share include inprocess research development iprd charge million diluted earning share relate acquisition tibotecvirco obtech medical exclude impact charge net earning increase net earning earning share include million diluted earning share million dilute earning share respectively related iprd alza merger cost iprd net restructuring gain detailed discussion charge refer note note consolidated financial statement description company contents johnson johnson billion sale letter shareholder world comprehensive broadly editorial section base manufacturer health care product board director provider relate service committee board consumer pharmaceutical medical device diagnostic market johnson johnson corporate officer company group chairman approximately employee corporate governance management responsibility operate company country management discussion analysis world selling product consolidate financial statement country note consolidated financial statement cover independent auditor report malvern pennsylvania facility centocor segment business geographic areas inc new monoclonal antibody manufacturing summary operation statistical data facility joyce salpan manufacture principal global affiliate associate foreground chaley larson senior worldwide family company supervisor work help company double capacity produce remicadeinfliximab corporate shareholderinvestor information rheumatoid arthritis crohns disease patientsletter shareholder william cweldon chairman chief executive officer trong performance segment company necessary investment broadly base health care business capital expenditure support growth enable johnson johnson achieve excep business strong free cash flow tional growth sale earning billion provide fuel billion share repurchase record sale billion represent growth program acquisition billion dividend operational growth curren increase refer early maintain exchange rate contribute favorable effect company outstanding triple credit rating time seven year set result context historical record net earning billion increase formance good year company exclude special charge lead diluted earning consistent long tradition growth share growth fact time achieve year year strong performance board director sale growth great depression increase quarterly dividend april earning growth remarkably consistent consecutive year quarter doubledigit gain exclude special charge quarter increase past year cash flow operation continue important way encourage strong billion net approximate longterm consistent performance invest million tax invest ment science technology theme pension plan year ensure continue report year deliver promise strength relevant monitor free cash technology evidence belief flow portion operate cash flow remain investment fundamental sustain james tlenehan vice chairman president establish leadership position permit deliver acquire orapharma inc specialty pharmaceutical superior return shareholder mean company recently announce agreement acquire ingful difference health care people world scios inc californiabase company product business segment treat congestive heart failure important biophar worldwide operation face future opti maceutical pipeline evidence strategy mism commitment opportuni hope conclude acquisition second quarter tie continue growth development pursue year growth manage set broad princi decentralize management system reflect ple maintain broadly base health care business strong performance give focus stress decentralize system management sense ownership local market dedicate manage long term foundation value empower management group quickly espouse credo pursue local avenue opportunity extraordinary record consistent performance focus manage company long term result broad base human health care increasingly sustain performance emphasize emphasize collaboration technology plat investment future importance true inno form enable proprietary position cypher vation invest billion research sirolimuselute stent promising example col development previous year laborative outcome achieve time pharmaceutical company recognize potential seize opportunity research development staff grow external licensing arrangement strategic acqui recently announce pende acquisition sition second quarter complete acquisition dimensional pharmaceutical outstanding organi tibotecvirco belgium organization focus zation strategic complement pharma develop antiviral treatment early year ceutical discovery development research capability engage threeyear capital invest drug administration fda approval levaquin ment program begin million additional indication treatment nosocomi worldwide research development pneumonia second common hospitalacquire business segment make major enhancement infection extend leadership contraceptive addition facility information market launch ortho evra contracep technology infrastructure accelerate ability tive patch ortho tricyclenlo new lowdose bring new product market deliver oral contraceptive promise technology product challenge finally significantly sustain consis europe small subset patient take eprex tent performance culture base subcutaneously chronic renal failure tak strong system value expect high standard ing erythropoietin see rare ethical behavior global organization occurrence pure red cell aplasia immune achieve assume responsibility lead response base continue investigation ership integrity guide pursuit issue implement labeling change eprex credo embodiment value provide patient important information place year safe method administration recog fourpart strategic business model broadly nize potential effect growth eprex base human health care decentralize manage result action urgent priority ensure long term foundation strong value safety patient rely product serve yield endure record consistent medical device diagnostic segment growth performance continue light way lead medical device business world repre future sent worldwide sale see operational term business performance growth strong sale growth successful year johnson johnson pharma achieve major area business include ceutical large fast grow cordis circulatory disease management product business segment worldwide pharmaceu depuy orthopaedic joint reconstruction spinal tical sale grow operational growth product ethicon wound care surgical sport medicine importantly growth area reflect women health product lifescan blood glucose performance number key product procrit monitoring product ethicon endosurgery minimally eprex treatment anemia continue invasive surgery product orthoclinical diagnostic realize new potential world professional diagnostic product vistakon dispos entry key competitor market man able contact lense date increase focus clinical competitive advan cypher sirolimuselute stent cordis tage go forward strong performer great example collaboration device risperdal antipsychotic pharmaceutical segment available file application use treatment bipolar country world fda approval disorder remicade treatment rheumatoid united states hope soon reim arthritis crohns disease bursement system europe constrain growth review indication immunemediate dis extent please level market ease duragesic transdermal patch chronic acceptance product breakthrough tech pain aciphexpariet proton pump inhibitor nology significant impact health gastrointestinal disorder approve wellbee patient additional indication symptomatic gastroin development include fda approval testinal reflux disease common cause vicrylplus suture ethicon suture peptic ulcer topamax antiepileptic antibacterial coating reduce potential surgi file monotherapy treatment cal site infection acquisition obtech medical prevention migraine headache adult market europe lead treatment morbid year company receive food obesity integration ethicon endosurgery business favorable fda panel recommendation board member retire april independenceibotmobility system maxine singer member board hope bring market robert wilson recently serve vision care franchise outstanding year senior vice chairman board bobs contribu particularly broad acceptance acuvue tion pharmaceutical business later penetration japanese market day corporate management board direction acuvue grow popularity acuvue instrumental growth decade colour tint contact lens greatly miss consumer segment continue deliver solid begin year enthusiasm formance represent total sale achieve exciting time ahead agenda focus operational growth combine skin key strategic imperative development care business neutrogena aveeno clean innovative product solution collaboration clearand rocsaw strong growth particularly broadly base health care business flawless execution emphasis superior science technology leadership acknowledge great heritage nutritional category notably splenda stand promise future nocalorie sweetener market leader fulfil build foundation table sweetener category ingredient strength strength recognize enormous brand sell country dedication power workforce viactivcalcium chew new bandaidbrand strong grateful effort liquid bandage help wound care franchise achieve continued allegiance shareholder strong growth example collaboration confidence harness prove technology case prescription deliver promise technology device dermabondtopical skin adhesive improve health care adaptation new market application backdrop confident position future performance evidence shift recent year business firmly root science technology high margin proprietary business offer opportunity sus william weldon taine profitable growth continue seize chairman board competitive advantage capitalize opportunity chief executive officer offer promise well health care people world strength leadership diversity experience background bring organiza tion key continued success thank de icate board director counsel provide james lenehan regard april welcome david satcher vice chairman board phd companys board director president satcher surgeon general united states director national center primary care morehouse school medicine regret accept resignation john snow march name cabinet position secretary treasury united states appreciate guidance pro vide member board wish service country acknowledge outstanding contribution deliver promise technology ur company drive mission improve human health care science technology promise fulfill mission deliver promise collaboration research process improvement dedication commit workforce common pursuit well health care people worldygolonhcet esimorp eht gnirevile remicade infliximaba mono clonal antibody treatment rheumatoid arthritis develop centocoris biologic therapy approve usfda induce maintain clinical remission patient moderate severe crohns diseasetanabe seiyakultdlaunche remicade japan crohns disease patients janssencilag ortho biotech european sale forcesare max imize pharmaceutical sale marketing technique new customer relationship management technology plan sale call share importantdata peer well serve customer johnson johnsonthrough orthomcneil pharmaceutical janssen pharmaceuticais found member prescription saving program thatprovide saving eligible medicare enrollee prescription product combine proprietary oros delivery technology yearsprocrit alza ascend dose profileconcerta epoetin alfa market methylphenidate hcl cii mcneil consumer specialty eprex erypo outside pharmaceutical extendedrelease formulation help million patient overcome anemia associate methylphenidate treatment attention deficit hyperactivity cancer chemotherapypre disorder minimize up down blood level dialysis kidney diseaseazttreate patient experience stimulant medication take time hivand certain elective surgery day last hour concerta demonstrate power eprex erypo indicate oros transform standard pharmaceutical tablet treatanemia dialysis patient advance drug delivery system use osmosis natural ment water semipermeable membrane oral drug administration control precise convenient incorporate commercialize product include concerta fda approve concerta extendedrelease tablet offer great dosing flexibility concerta approve country europe latin america asia show katya alvarez successful college student adhd symptom control concerta get help head dormito dad julio alvarez mcneil district manager acquisition tibotecvirco expand drug discovery research development capabilitiesparticularly field antiinfectivesthe belgiumbase biopharma ceutical company bring johnson johnson promising compound development treatment hiv number innovative disease management tool tibotec apply late technique ultrahigh throughput screen antiviral profiling molecular biology drug design discover develop new antiinfective drug company program focus potential drug active drugresistant strain hiv include product early clinical development additionally early stage research program concentrate treatment infectious disease include hepatitis virco develop market advanced diagnostic tool base pharmacogenomic principle clinical management viral infection include hiv feature leave right gery dams senior scientist koen van acker research fellow paula mckenna director diagnostic lab operation create new option health care range discipline pharmaceutical agent medical devicesdiagnostic delivery platform consumer product broadly base focus human health care compound derive small molecule smart technology compensate frailty disease patent formulation serve grow consumer need alza focus sophisticated drug delivery technologybase product expand theconstruction manufacturing facility cashelireland product incorporate drug delivery technology alza widely commercialize com panie inside outside johnson johnson deliver unique patient advantage cashel plant squarefoot facility ample room future expansion add critical capacity manufacture product grow european marketplace time reduce pressure production supply chain operation united states improve efficiency enhance service cashel site represent share com mitment alza johnson johnson engineering technical resource create manufacture center excellence drug delivery technology say robert strickland managing director cashel facility show company expect begin ship product facility quarter deliver promise technology aciphex rabeprazole sodium copromote eisai incand janssen pharmaceutica incand prescribe gastroesophageal reflux diseasewa approve usfda partof sevenday treatmentfor hpylori infectionthe mostcommon cause peptic ulcer usfda approve levaquin levofloxacin tabletsinjection levaquin levofloxacin dextrose injection treatmentof nosocomial hospitalacquire pneumonia intricatestateoftheartcomputing research net levaquin fluoroquinolone antiinfective orthomcneil work laboratory connect major research facility pharmaceuticalinc throughoutthe companywa create johnson johnson clinical study anti network computing service ncs facilitate product design epilepsy medication topamax creation alleviate roadblock geographic topiramatetopiramate capsule time zone difference company room tablet sprinkle capsule johnson johnson location world global researcher use orthomcneil pharmaceutical incdemonstrate significant advanced communication tool highdefinition visualization effecton control seizure model science way typically visible human newlydiagnose patientseven eye grid collaboration connect person diverse loca standalone therapy tion internet research network leadingedge technol ogy enable massive amount datum exchange time expect help johnson johnson business reduce time takes bring product marketplace james regina vice presi dent technology engineering development nc leave stuart kippelman director advanced technology research picture prototype collaboration system nc ygolonhcet esimorp eht gnirevile regulatory agenciesof germany ukwere firstto approve risperdal consta risperidone janssencilag firstatypical antipsychotic available form long act injectionthis form approve european coun try new zealandmexico israel korea johnson johnson acquire orapharmainca specialty pharma ceutical company focus developmentand commercialization uniquepatente therapeutic orapharma operate partof personal product company provide entry oral care professional marketplace initial focus treatmentand prevention periodontal disease process excellence major focus atjohnson johnson result important solutionsto wide range formi dable challenge solution successfully implement ortho tricyclen lonorgesti increase number patient begin raise concern mateethinyl estradiol ortho mcneil pharmaceuticalincis key product market janssen duragesicfentanyl transd newlowdose version mal system medicate patch provide day relief mostprescribe birth control pill patient chronic pain apparently detach skin usortho tricyclen process excellence team janssen include member norgestimateethinyl estradiol johnson johnson company charge resolve low level estrogenthe new version highly effective problem team lead director process excellence chris herbine leave director marketing jim eckhardt right follow ukregulatory authority specific analytical improvement methodology conclude grant janssencilag ltdan exten sion license durogesic detach problem relate patient improperly apply fentanyl transdermal system patch design program center educational material cancer include type clearly describe proper way apply patch plan severechronic painalso ensure patient caregiver health care professional janssen pharmaceutical kkin japan launch product use product access information result call durotep cancer pain percent reduction complaint rate twoyear period improvement customer satisfaction contribute sub stantial increase duragesic sale centocor double manufacturing capacity remicade infliximab new malvern pennsylvaniafacility fully operational mid remicade monoclonal antibody treat patient rheumatoid arthritis patient gastrointestinal disorder crohns disease hundred thousand patient treat worldwide remicade fully capable meeting current market demand remicade centocor poise maximize potential product market world facility show valerie ulicny monitor process large advanced mammalian cell culture bio pharmaceutical bulk production center world addition malvern operation centocor produce therapeutic agent monoclonal antibody technology leiden netherlands employ dedicated people stateoftheart facility work worldwide provide resource need workforce future focus imperative enable meaningful contribution collaboration disciplinary line unique advantage broadly base company acquisition inverness medical limited iml strengthen ability lifescan serve global diabetes market help enhance company commit ment improve quality life people diabete inverness facility manufacture test strip diabete patient blood glucose selfteste lifescan onetouch ultra induo onetouchultrasmart smartscanand euroflashsystem need expand research development capability production capacity iml recently initi ate new construction substantial capital investment facility inverness scotland enable iml bolster pro duction test strip increase new product development picture check quality card strip thomas stevenson manu facture team leader leave nigel spiller manufacturing director deliver promise technology stringent quality production standard pharmaceutical manufacturer janssencilag apply new cypher sirolimuselute stentgive cordis unique advantage market worldwide available country world expect available year lap disc hand access device united states cypher stent report reduce rate introduce ethicon endosurgery reblockage coronary artery bare metal stent current treat handassisted laparoscopic ment clog artery prevent reblockage occur surgery itis enable invasive painful surgical procedure approximately percent world stent patient trial follow reduce hospitalization month binary instent restenosis reblockage recovery time compare occur percent case cypher stent traditional surgery addition latina italy facility janssencilag surgifoam absorbablegelatin francesca finocchiaro picture inspect coat stent cypher powder johnson johnson stent manufacture janssen facility beerse belgium wound managementis plant begin partnership device phar hemostatic powder thatcome maceutical technology lead development cypher selfcontaine sterile mixing vessel itcan spread shape con stent possible diversity interest human health form irregular surface stop care distinct johnson johnson company bleed fast prolene patchpolypropylene mesh ethicon productsan innovative threedimensional device repair abdominal wall herniasoffer simplestreamline insertion techniqueitis design preventmigration recur renceand provide new diman sion comfortand healing monarch spinesystemfrom depuy acrome comprehensive pedicle screwrod hook system immobilization stabilization spinal segment treat mentof acute chronic instabili tie deformity thoracic lumbar sacral spine eht gnirevile ethicon endosurgeryexpande mammotome breastbiopsy system productline intro duce new probe sizeswhich increase number lesion thatcan biopsie minimallyinvasive technique watchband incisionintro duce cardiovationsa division ethiconinccombine multiple technology enable endo scopic radial artery harvesting result significantly small scar thatcan hide watchband offer potential trauma largeincision surgery japan represent importantglobal market ethicon endosurgerycompany percutaneous transluminal coronary group chairman karen licitraright angioplasty ptca balloon manufacture lpga hall famer kathy whitworth green atthe cordisthe aqua tptca balloon catheter annual ethicon endosurgery pink available market united states ribbon lpga proam benefitin develop cooperation cardiologist supportof breastcancer research japan make easy interventional cardiolo gynecarea division ofethiconinc gist cross treat challenge lesion introduce new productto com unique attribute balloon innovative plementit establish gynecare tvt tensionfree supportfor seal technology make efficient incontinence productlinethe delivery balloon design navigate gynecare tvt abdominal smoothly tortuous anatomy taper guidesoffer broad group tip aids cross tight lesion aqua health care professional option balloon catheter launch japan treatthe grow female stress urinary incontinence market benelux region europe release world market exclude united states half cordis associates donna sakaguchi shinichi miyata confer taro saito interventional cardiologist kumamoto research drive discovery devel opment investment facility technology possible discovery development new health care solution normal pressure hydrocephalus nph afflict people usand thousand worlda form hydrocephalus characterize abnormal accumu lation cerebrospinal fluid ventricle brain devastating disease difficult diagnose go untreated cause symptom difficulty walk mild dementia uri nary incontinence nph treat case symptom reverse codman hakimprogrammable shunt system codman world leader neurosurgical implant surgical product introduction codman hakim programmable valve system use programmer adjust pressure valve non invasively cranial shunt implant need surgical adjustment eliminate nph patient receive codman hakim programmable valve bob fowler right dallas texas meet michael mcintyre senior product directorhydrocephalus codman acquisition swissbase obtech medical provide ethicon endosurgery opportunity offer surgeon minimallyinvasive alternativeexpand extensive line product treatment morbid obesity strengthen competitive position advanced technology exemplifie way ethicon endosurgery continually seek respond diversify need surgeon patient swedish adjustable gastric band sagb inflatable band fit uppermost stomach laparo scopic surgery create small pouch food intake greatly reduce result weight loss physician able adjust band inner diameter time inject remove fluid access port available sagb widely europe treatment morbid obesity market country karl miller leave hallein austria team include dietician monika zeiner seat work company representative franz buchner right provide education support patient hone process flawless execution grasp investment efficient possible enable fulfill mission improve quality life deliver promise technology onetouch ultrasmartblood glucose monitoring system lifescana meter electronic logbook oneautomatically organize blood glucose result importantdiabete informa tion meaningful chart graph help people well man age diabete advanced diagnosticsystem ad division orthoclinical diagnostic focus high impactproduct human cancer diagnosismonitoringscreene patientmanagementdavid atkin general manager molecular diagnostic group ad apply genomic tool ordinarily drug discovery molecular diagnostic productdevelopment promogran matrix wound dressingfrom johnson johnson wound managementwa intro introduction prepackage sterile duce chronic wound bandage development firstever dress thatcombine oxidize regenerated cellulose collagen antibacterial suturethe medical device company johnson itis indicate treatmentof johnson usher new generation surgical care exuding wound includingbutnot limit todiabeticvenous yearend launch vicrylplus antibacterial suture pressure ulcer ethicon product introduce new era device help reduce risk complication associate surgery vitro stud preservation minimally invasive unicompartmental knee ies demonstrate vicryl plus effective bacteria depuy orthopaedic enable cause surgical site infection united states restoration softtissue balance surgical site infection occur annually cost assure natural function billion medical system percent alignmentitis system integrate fix mobile surgical site infection occur incision site vicryl plus bear component minimally antibacterial suture handle characteristic vicryl invasive knee reconstruction suture world widely absorbable suture howard scalzo staff engineer punam aggarwal managernew product integration show examine active zone suture laboratory dish eht gnirevile viactiv softcalciumchewsfrom mcneil nutritional avail able milk chocolatemochaccino caramel orange cream flavor chew provide percentof daily value calcium splenda caloriesweetener mcneil nutritional lead low calorie sweetener usgrocery marketsplenda find prod uct country vistakon division johnson johnson vision careincintroduce acuvue colour brand contact lenseswhich offer natural color superior comfortlaunche glob ally acuvue coloursis independence technology deliver inaugural number lens commitment year ago bring new freedom uscosmetic tintsegment people mobilityrelate disabilitiesin late new toothbrush launch orthopaedic rehabilitation device panel food personal product companyreach drug administration fda unanimously recommend approval maxis clinically prove reduce gingivitisit rubber bristle independenceibotmobility system fda massage gum multilevel approval hope second quarter bristle clean hardtoreach place independence ibot mobility system navigate uneven terrain help preventgum disease climb stair ramp balance stand height neutrogena menis clinically wheel late acquisition lead recent introduction prove line skin care product independenceiglidemanual assist wheelchair respond mens specific skin use proprietary technology continuously monitor care needsthe line contain razor defense skin clearing prod force need propel chair different type terrain user uct design turn problem skin propel chair carpet similarly difficult terrain healthy look skin effort traditional manual wheelchair reduce incidence common problem rotator cuff injury carpal tunnel syndrome united states estimate million people use wheelchair show sandy salerno occu pational therapist independence technology acquaint william scelza independence iglide manual assist wheelchair cultivate leadership people commit make measurable difference corporation future global contributor well health care brand expansion customer development strategy help johnson johnson worldwide baby product business continue growfor example global retail operation dynamic latin america market focus key franchise consumer business region hold number market position world innovation result insight consumer preference serve expand market grow sale recent launch products johnsonsbaby shampoo curly hair available latin america country appropriate family member exemplify importance market expansion line exten sion brandbuilde creative merchandise con cept picture retail outlet buenos aires argentina marita messuti trade marketing manag consumer business johnson johnson argentina cel company see seize promise technology improve quality life company researcher work world lead skin care scientist bring marketplace array technologydriven skin care product fulfill consumer need age johnson johnson primarily compete traditional skin care arena include facial body hand care continu ous growth franchise achieve johnson johnson consumer product company comprehensive adult skin care franchise clean clear aveeno roc purposeand shower showerbrand steady stream beneficial skin care product neutrogena ensure skin care prod uct meet customer need company conduct extensive market research create innovative marketing program example clean clear cast sponsor conjunction television network showcase clean clear product help brand lead teen skin care line marketing staff member include john weinstock group product director clean clear picture work beauty consultant travel exhibit deliver promise technology revolutionary liquid bandage change way consumer treat minor cut scrapeswas introduce johnson johnson consumer product company bandaidbrand liquid bandage provide superior protection optimal healing stay hardtocover area like finger tylenol sinus tylenol knuckle bandage create clear seal keep water colddaynightconvenience pack germ help prevent infection promote quick healing mcneil consumer specialty stay naturally slough wound heal bandaid pharmaceutical contain brand liquid bandage contain octyl cyanoacrylate base package day night formula relieve day night material find dermabondtopical skin adhesive prescription time symptom sinus pain device market ethicon product manufacture cold convenientbox closure medical corporation physicians close wound johnson johnson consumer incision place stitch staple dermabond adhesive act product companysigne agree barrier seal bacteria lead infection mentto acquire compeed ethicon product introduce thick formulation dermabond product business worldwide provide well control physicians michael haddadeast coloplastasthe acquisition ern division manager picture check major retail account shelf provide worldwide access comprehensive line patent face new bandaidbrand liquid bandage technology platform develop strong european wound care presence simply stuffy andsimply coughare single ingredient product child mcneil consumer specialty pharmaceu ticalscontaine thatmedicine need specific condition nasal decongestantand cough suppressant cough cold aveeno positivelyradiant daily moisturizer johnson johnson consumer product company use patent technology base effectof small protein soy diminish appear ance skin pigmentationclinically provenitgive skin tone smooth texture una gran familiacampaign tylenol acetaminophen fea ture employee mcneil con sumer specialty pharmaceutical las piedraspuerto ricoin television commercial didntdrive million milesor plant acre treeswe reduce emission save year solar panel neutrogenathe square foot panel large com mercial solar rooftop installation california generate elec tricity day power home develop close johnson johnson pediatric partnership city los angeles reduce operate institutellcis dedicated advancementof maternal chil cost monthly energy consumption company drens health carein partnership cent senaka nanayakkara neutrogena director facilities engineer health care professionalsdevel ing angelina galiteva director strategic planning los angeles opmental specialist interna department water power discuss initiative project tional organizationsthe institute undertake initiative thathelp neutrogena exemplify johnson johnson commitment shape future children health use renewable energy resource burn fossil fuel large manmade source greenhouse gas atmosphere human health dependson health planetand com contribute climate change johnson johnson energy conser pany recognize link conser vation goal establish aggressive target reduce green vation earth biological house gas emission past decade carbon dioxide emission diversitypartnership increase modest percent nature conservancy world wildlife fund advance thatpurpose improve quality life mcneil canada achieve imme diate percentreduction emission conver sion company fleetvehicle percentethanolbase fuel availablethe company rec ommend use efficientfuel employee campaign nursing futuresm sponsor johnson johnson address critical shortage nursesis usinitiative recruit retain nurse nursing facul tyitinclude national advertising fundraising eventsrecruiting mate rial website surgical eye expedition johnson johnson provide fund selfsustaine eye clinic serve poor uninsured juarezmexicosince open julythe clinic examine patientsabout percent return surgery completion clinic bove remember longstanding commitment customersour employee shareholder community live work yalejohnson johnson physician scholars international health program put physician hospi tal country limit health technology resourcesparticipant learn application profe sion develop country share medical knowledge people johnson johnson funding enable yale expand offer physician residency training lead hospi tal university offer international opportunity experience career physician academic year nearly physician enrol program program begin doctor include kimberly curseen show leave tracyann clarke right par ticipate accord yale study program alumni exhibit care attitude health care delivery especially poor underserved community nonparticipant counter part research show patient respond favorably treatment doctor compassionate sensitive board director william weldon david satcher leo mullin chairman board director national chairman chief director center primary care executive officer chief executive officer delta air lines inc robert darretta henry schacht ann jordan executive vice president director senior advisor director finance information lucent technologies inc social service management chief department chicago financial officer lyingin hospital committees board audit benefit compensation audit committee compose benefit committee compose compensation committee entirely nonemployee director entirely nonemployee director compose entirely nonemployee help board oversee company review management vari director review compensation accounting reporting practice ous retirement pension health philosophy policy nonboard recommend independent public welfare plan cover substantial management compensation committee accountant appointment employee company respect executive compen board review performance domestic operation employee sation fringe benefit monitor adequacy internal certain international subsidiary compensation matter committee accounting practice procedure committee monitor administer company stock control review significant performance trust option plan determine change accounting policy pension fund invest compensation member executive committee james cullen chairman maxine singer phd chairman arnold langbo arnold langbo chairman leo mullin james cullen henry schacht gerard burrow maxine singer phd james lenehan president chief president carnegie vice chairman executive officer institution washington board directors sea research foundation president robert wilson judah folkman arnold langbo james cullen senior vice chairman senior associate retire chairman retire president board director surgery director board chief chief operating officer children hospital executive officer bell atlantic corporation professor cell biology kellogg company harvard medical school finance process performance evaluation ann jordan chairman finance committee exercise committee board russell deyo management authority board additionally committee review judah folkman intervals board company management succe david satcher meetings sion plan executive resource science technology william weldon chairman henry schacht chairman science technology advisory robert darretta gerard burrow committee composed board mem james lenehan ann jordan ber company vice president leo mullin science technology advise board scientific matter include nominate corporate governance public policy major internal project interaction nominate corporate public policy advisory committee academic outside research governance committee compose compose board member organization acquisition entirely nonemployee director company vice president administra technologies product responsible oversee corporate tion review company policy governance matter review possible program practice public gerard burrow chairman candidates board membership health issue environ judah folkman recommend nominee election ment health safety raymond ruddon phd committee responsible employee advise make david satcher evaluate function perfor recommendation board maxine singer phd mance board oversee issue corporate officer company group chairman corporate officer william weldon russell deyo john papa chairman board directors vice president administration treasurer chief executive officer executive committee chairman executive committee brian perkin michael dormer worldwide chairman james lenehan worldwide chairman consumer pharmaceutical vice chairman board director medical devices nutritionalsgroup president executive committee executive committee executive committee roger fine peterson phd robert wilson vice president general counsel chairman research development senior vice chairman executive committee pharmaceutical group board directors executive committee vice chairman executive committee colleen goggin worldwide chairman larry pickere andrea alstrup consumer personal care group vice president corporate development vice president advertising executive committee christine poon michael carey thomas gorrie phd worldwide chairman vice president human resource vice president pharmaceuticals group government affair policy executive committee stephen cosgrove corporate controller joann heffernan heisen raymond ruddon phd vice president vice president science technology robert darretta chief information officer executive vice president executive committee michael ullmann finance information management secretary chief financial officer willard nielsen associate general counsel executive committee vice president public affairs company group chairmen robert croce executive committee johnson william dearstyne johnson principal management carlos gottschalk group responsible operation walter hak allocation company resource karen licitra addition executive committee dennis longstreet member serve chairman group eric milledge operate committee com patrick mutchler prise manager represent key david norton operation group gerald ostrov management expertise specialized jose sartarelli phd function committee oversee joseph scodari coordinate activity domestic curt selquist international company relate pericle stamatiade consumer pharmaceutical gerard vaillant medical device diagnostic business nicholas valeriani operating management company carol webb head chairman president general manager managing director report directly line executive group operating committee corporate governance management responsibility johnson johnson govern value set forth audit committee board director compose credo create general robert wood johnson solely independent director financial knowledge principle guide year continue experience provide appropriate oversight review set tone integrity entire company level internal control matter key accounting financial employee johnson johnson commit ethical reporting issue audit committee regular basis principle embody credo principle addition independent auditor general counsel weave fabric company vice president internal audit regularly meet private se credo value extend account financial sionswith audit committee discuss result report responsibility shareholder work include observation adequacy internal finan investors management johnson johnson cial controls quality financial reporting confirm responsible integrity objectivity accompany properly discharge responsibility rele financial statement relate information vant matter responsible ensure financial datum report accurately regularly review business result strategic prior manner facilitate understand data itie executive committee continuously involve evidence commitment responsibility review financial result develop maintain strong system internal accounting control standing strategy key initiative long term growth encourage strong effective corporate governance intent ensure maintain objectivity business board director continuously review business result assessment constructively challenge approach business strategic choice focus financial stewardship opportunity issue monitor business result corporate staff professionally train internal audi relate control tor travel worldwide monitor system internal consolidated financial statement financial datum accounting control design provide reasonable follow responsibility management statement assurance asset safeguard transaction prepare conformity accounting principle event record properly internal control generally accept united states america include include selfassessment internal external audit amount base good judgment commit review operating company require ted provide timely accurate understandable informa management team operate company certify tion shareholder compliance policy business conduct systematic program ensure compliance policy employee level pricewaterhousecooper llp company independent auditor engage audit financial statement pricewaterhousecooper llp maintain understand william weldon robert darretta internal control conduct test audit chairman board executive vice president procedure consider necessary circumstance express director chief finance information opinion independent auditor report executive officer management chief financial officer table content management discussion analysis overview organization description segment operate result financial position capital resource matter audit consolidated financial statement consolidate balance sheet consolidate statement earning consolidate statement equity consolidate statement cash flow note consolidated financial statement independent auditor report segment business geographic area summary operation statistical data management discussion analysis result operation financial condition overview description business record sale billion exceed sale company approximately employee worldwide billion mark year consecutive engage manufacture sale broad range prod positive sale growth growth lead strong uct health care field company sell product performance pharmaceutical medical device virtually country world company primary diagnostic segment interest historically currently product balance sheet remain strong cash generate relate human health wellbeing operation billion cash dividend share pay company organize principle decentralize shareholder increase rep management executive committee johnson johnson resent consecutive year cash dividend increase principal management group responsible opera company continue company tion allocation resource company triple credit rating committee oversee coordinate activitie domestic international company span consumer organization pharmaceutical medical device diagnostic segment management objective international subsidiary exception company objective achieve superior level capital manage citizen country locate efficient profitable growth accomplish company product line company competes compa management operate business consistent certain ny large small locate united states strategic principle prove successful time america abroad competition strong line end company participate growth area human regard number size compete company health care commit attain leadership position involve competition research involve development inthese growth segment development innova improvement new exist product tive product service approximately billion process particularly significant result time sale invest research development rec time product process obsolescence development ognize importance ongoing development new new improved product important company suc differentiate product service cess area business competitive environment company system management operate decen require substantial investment continue research tralize basis operating company locate inmultiple sale force addition win retention country company view management philosophy customer acceptance company consumer product asset fundamental success broadly base involve heavy expenditure advertising promotion business foster entrepreneurial spirit combine description segment theextensive resource large organization ability react quickly local market change challenge consumer business manage long term order sustain consumer segment principal product personal leadership position achieve growth provide care include nonprescription drug adult skin hair care endure source value shareholder product baby care product oral care product aid prod unifying management team company dedi uct women health product nutritional product cat employee achieve objective johnson product market principally general public dis johnson credo credo provide common set value tribute wholesaler directly independent serve constant reminder company responsibility chain retail outlet world major brand customer employee communitie shareholder skin hair care line product include neutrogena company believe basic principle roc aveeno clean clear johnson piz overall mission improve quality life people buinand sundownsun care product shower enable johnson johnson continue showerpersonal care product major brand leader health care industry thecounter line product include broad family result corporate governance issue atcer tylenolacetaminophen product adult children tain company government lawmaker enact sarbane motrinanalgesic product imodium mylantaand oxley act protect investor improve accuracy pepcidacid controller johnson johnson merck reliability corporate disclosure light legislation consumer pharmaceutical major brand women company establish document formal health care line product include carefree stayfree process exist internal control like obtampon monistat major brand baby care annual certification compliance management line product include johnsonsbaby line product policy business conduct company continue evaluate penatenand natusanbaby care product major enhance internal control process additionally aid product include bandaidbrand adhesive company continue maintain strong ethical environment bandage compeed major oral care product include johnson johnson credo overall guide reachbrand toothbrushe major product nutrition al product line include splenda noncaloric sugar substi tute viactivcalcium chews benecolfood product pharmaceutical medical device diagnostic pharmaceutical segment principal worldwide franchise medical device diagnostic segment include broad antifungal antiinfective cardiovascular contraceptive range product direction health care dermatology gastrointestinal hematology immunology professional product include ethicon wound care neurology oncology pain management psychotropic central surgical sport medicine women health product ethicon nervous system urology field product endosurgerys minimally invasive surgical product cordis cir distribute directly wholesaler health culatory disease management product lifescan blood glucose care professional use prescription general public monitoring product orthoclinical diagnostic professional prescription drug antifungal field include nizoral diagnostic product depuy orthopaedic joint reconstruction ketoconazole sporanoxitraconazole terazolter spinal product vistakon disposable contact lense conazole daktarintmmiconazole nitrate antifungal product principally professional field product prescription drug antiinfective field include physicians nurse therapist hospital diagnostic laboratory floxinofloxacin levaquinlevofloxacin prescrip clinic acquisition medical device diagnostic tion drug inthe cardiovascular field include retavase segment recent year integral reteplase recombinant biologic cardiology care product ongoing process transform medical supply business treatment acute myocardial infarction improve blood serve arange high technology medical specialty flow heart reoproabciximab treatment operating result acute cardiac disease prescription drug contraceptive field include sale ortho evranorelgestrominethinyl estradiol transdermal worldwide sale increase billion system orthonovumnorethindroneethinyl estradiol compare increase tricilestnorgestimateethinyl estradiol sell sale large distributor amerisourcebergen asortho tricyclen group oral contraceptives corp mckesson hboc cardinal distribution account prescription drug dermatology field include retina respectively total revenue exclude microtretinoin dermatological cream acne prescrip impact foreign currency worldwide sale increase tion drug gastrointestinal field include aciphex price increase rabeprazole sodium proton pump inhibitor treating account approximately growth erosive gastroesophageal reflux disease gerd duodenal respectively ulcersfrom company derive service revenue sale domestic company billion product copromote inthe eisai imodium billion billion represent loperamide hcl antidiarrheal motiliumdomperidone increase agastrointestinal mobilizer remicadeinfliximab sale international company billion novel monoclonal antibody treatment certain crohns billion billion represent disease patient remicadeis indicate treatment increase rheumatoid arthritis exclude impact foreign currency fluctuation prescription drug hematology field include procrit past year sale international company epoetin alfa sell outside eprex biotechnology increase derive version human hormone erythropoietin year annual compound growth rate sale stimulate red blood cell production prescription drug exclude impact foreign currency fluctuation immunology field include orthocloneoktmuromonab annual compound growth rate sale year reverse rejection kidney heart liver period transplant prescription drug neurology field include geographic area world post opera topamaxtopiramate reminylgalantamine tional gain exclude effect exchange rate stugeroncinnarizine prescription drug oncology fluctuation dollar foreign currency field include doxildoxorubicin anticancer treatment sale increase europe western ergamisollevamisole hydrochloride colon cancer drug hemisphere exclude asiapacific leustatincladribine hairy cell leukemia africa region include impact currency fluctuation prescription drug psychotropic central nervous sys sale increase europe asiapacific tem field include antipsychotic drug risperdalrisperidone africa decrease western hemisphere exclud haldolhaloperidol concertamethylphenidate ing company achieve annual compound attention deficithyperactivity disorder prescription drug growth rate worldwide sale year period pain management field include duragesicfentanyl trans domestic sale grow rate dermal system sell abroad durogesic transdermal international sale grow rate exclude patch chronic pain ultracettmtramadol hydrochlo impact foreign currency fluctuation annual compound ride analgesic moderate moderately severe pain growth rate year period prescription drug urology field include ditropan oxybutynin treatment overactive bladder consumer segment sale billion second quarter company complete increase increase consumer acquisition tibotecvirco approximately mil segment sale prior year operational growth lion tibotecvirco privatelyheld biopharmaceutical currency negatively impact sale growth company focus develop antiviral treatment sev domestic sale increase international sale gain eral promise compound development treatment local currency offset negative currency infectious disease include hiv impact result total international growth fourth quarter company receive consumer sale achieve strong growth skin care product food drug administration fda approval neutrogena clean clearand aveeno band levaquinlevofloxacin additional indication aid wound care product mcneil nutritional treatment nosocomial pneumonia second common splendasweetener product viactivcalcium chew hospitalacquire infection company file new consumer segment sale billion drug application fda include topamaxtop increase domestic sale increase iramate prevention migraine headache adult international sale gain local currency use monotherapy treatment epilepsy offset negative currency impact result total currently approve adjunctive treatment levaquinfor growth consumer segment sale bil fiveday treatment communityacquire pneumonia lion increase domestic sale increase risperdalrisperidone adjunctive monotherapy international salesgain local currency treatment bipolar disorder offset negative currency impact result fourth quarter company announce total decrease definitive agreement acquire orapharma inc specialty pharmaceutical segment sale billion pharmaceutical company focus development com increase include growth domestic mercialization unique therapeutic oral health care prod sale total growth international sale include uct acquisition provide entry oral health positive effect currency increase professional marketplace provide synergistic line pre pharmaceutical segment sale prior year vention treatment product maintain periodontal health operational increase currency positively impact sale transaction value approximately million net growth cash close quarter sale growth reflect strong performance pharmaceutical segment sale billion procriteprex treatment anemia remicade total increase include growth treatment rheumatoid arthritis crohns disease domestic sale operationally international sale increase risperdal antipsychotic medication duragesic partially offset negative currency impact transdermal patchfor chronic pain topamaxan anti result total growth pharmaceutical segment epileptic medication sale procriteprexaccounte sale billion increase total company revenue include growth domestic sale operationally interna johnson johnson markets prescription drug tional sale increase offset nega world sale generate outside tive currency impact result total decrease sale united states thirtythree drug sell company sale growth partially offset restrict access sale excess million excess million propulsidin number market world rate growth sale procritand eprexwa worldwide sale billion medical slow half result new competition device diagnostic segment represent increase procrit sale growth affect currency impact sale growth rare report pure red cell aplasia prca chronic renal total increase operational sale increase failure crf patient administer eprexsubcutaneously prior year domestic sale international company ongoing investigation prca crf patient sale increase prior year indicate occurrence prca continue rare strong sale growth achieve major fran chise segment cordis circulatory disease manage ment product depuys orthopaedic joint reconstruction spinal product ethicon wound care surgical sport medicine women health product lifescan blood glucose monitor ing product ethicon endosurgerys minimally invasive surgical product orthoclinical diagnostic professional diagnostic product vistakon disposable contact lense quarter company announce gross profit final result sirius landmark study gross profit margin improvement cyphertmsirolimuseluting stent drugelute coronary gross profit margin improvement stent kind recommend fda gross profit margin gross profit approval clinical result cyphertmstent indicate sig margin improvement nificant reduction instent restenosis revascularization improvement gross profit margin past year rate compare bare metal stent finding confirm primarily result continue improvement mix stent continue excellent performance significantly business successful ongoing cost control effort reduce reblockage coronary artery patient sellinggeneral administrative expense coronary artery disease additionally july consolidate sell general administrative expense department health human service hhs increase respec decision provide accelerate incremental reimbursement tively sell general administrative expense percent tohospital technology commence april sale undernewly establish diagnostic relate group drg respectively result implementation inorder ensure access technology patient emerge issue task force eitf issue account rapidly possible hhs take unprecedented step consideration give vendor customer reseller assign new drg prior fda approval october vendors products company reclassify million circulatory system device panel advisory panel vote million respectively fromselle favor fda approval recommend condition general administrative expense reductionof sale forthe company drugelute coronary stent company reclassify million million expense continue work fda ongoing review respectively sell general administrative product approval expense cost product sell fourth quarter fdas orthopaedic advertising expense comprise television radio rehabilitation device panel unanimously recommend favor print medium internet advertising billion fda approval condition independencetm billion billion ibottmmobility system ibottmmobility system unique device offer benefit individual mobility research expense relate disability device navigate difficult research activity represent significant terrain climb stair ramp balance stand height company business expenditure relate develop twowheel ment new product improvement exist product december ethicon receive fda clearance mar technical support product compliance governman ket vicrylplus antibacterial suture suture tal regulation protection consumer patient design antibacterial agent design reduce bacte worldwide cost research activity exclude inprocess rial colonization suture vicrylplus help reduce research development charge follow risk complication associate surgery million dollar worldwide sale billion medical research expense device diagnostic segment represent total increase percent increase domestic sale interna prior year tional sale increase sale gain local currency percent sale offset negative currency impact research expense percent sale pharmaceutical worldwide sale billion medical device segment diagnostic segment represent total increase average consumer consist gain local currency medical device diagnostic segment reduce strength dollar domestic respectively sale international sale increase significant research activity continue pharma sale gain local currency offset negative ceutical segment spending increase billion currency impact represent compound annual growth rate ofapproximately forthe fiveyear period johnson johnson pharmaceutical research development llc know janssen research foundation johnson pharmaceutical research institute pri mary worldwide pharmaceutical research organization additional research conduct centocor alza corporation alza tibotecvirco collaboration james black foundation london england inprocess research development amgen retain exclusive right second quarter company record warrant extraordinary remedy terminate contract process research development iprd charge mil instead find amgen adequately compen lion aftertax million tax iprd generally sate monetary damage arbitrator award tax deductible relate acquisition acquisi million damage record quarter tion include tibotecvirco privatelyheld biopharma arbitration fourth party ceutical company focus develop antiviral treatment january arbitrator rule obtech medical privatelyheld company market amgen prevail party arbitration entitle adjustable gastric band treatment morbid obesity itto award reasonable attorney fee cost amgen fourth quarter iprd charge mil submit application fee cost lion aftertax million tax iprd generally company expense million fourth quarter tax deductible incur result acqui inconnection outstanding claim sition inverness medical technology supplier lifescan addition item indicate electrochemical product blood glucose monitoring follow income expense include cost relate merger e spinoff nondiabete business terame withalza million amortization expense early stage medical device company develop endova approximately million long require cular stentgraft system minimally invasive treatment financial accounting standard board fasb standard abdominal aortic aneurysm peripheral occlusive disease goodwill intangible asset sfas company iprd charge million addition item indicate aftertax million tax iprd generally income expense include favorable adjustment cost taxdeductible relate acquisition associate global manufacturing restructuring atrionix inc development stage company primary charge gain sale product line product pulmonary ablation catheter treatment earning provision taxis income atrial fibrillation crescendo company form alza consolidated earning provision taxis income forthe purpose select developing commercialize increase human pharmaceutical product respectively exclude iprd merger charge note interestincome expense inthe previous section increase interest income decrease primarily decline respectively increase interest rate cash expend stock primarily volume growth improve gross profit repurchase program average yield marginsand efficiency spending sell marketing investment basis point aver administrative expense age yield interest expense compare operate profit segment follow remain relatively constant significant percent change average debt balance sale income expensenet million dollar income expense include gain loss relate consumer thesale writedown certain equity securities pharmaceutical johnson johnson development corporation loss med device diag disposal fix asset currency gain loss minority segment total interest litigation settlement expense royalty expense income additionally income expense include allocate gain sale ortho pref product line segment impact amgen arbitration settlement october arbitrator chicago deny earning effort amgen inc terminate license agreement taxis income ortho biotech obtain exclusive right toamgendevelope erythropoietin epo sell procriteprex indication outside kidney dialysis amgen file suit claim ortho biotech breach license right improperly make sale epo amgen exclusive dialysis market decision arbi trator find sale market increase expense allocate segment primarily netincome earning share decline interest income discuss worldwide net earning billion reflect interest income expense section increase worldwide net earning share consumer segment operating profit increase equal share increase prior year reflect operate profit percent sale net earning share exclude impact improvement improvement primarily iprd impact iprd merger cost leverage ofselling promotion administrative expense worldwide net earning billion net earning offset increase expenditure advertising additionally share represent increase theconsumer segment operating profit improve respectively impact nonamortiza amortization expense long require sfas tion sfas increase net earning earning pharmaceutical segment operating profit increase share approximately worldwide net earning achieve reflect operate profit percent sale improvement ayear annual growth rate earning share pharmaceutical segment operating profit nega grow rate exclude impact accounting tively impact cost amgen arbitration settlement change iprd worldwide net earning million damage million legal fee achieve year annual growth rate earning iprd relate tibotecvirco acquisition offset share grow rate year annual compound gain sale ortho pref product line growth rate net earning earning share impact ofsfas operating profit percent respectively exclude impact iprd sale pharmaceutical segment pharmaceutical seg merger cost worldwide net earning achieve year annual ment operating profit include effectof leverage growth rate earning share grow rate marketing expense pharmaceutical operating profit include expense relate merger alza worldwide net earning billion reflect medical device diagnostic segment operating profit increase worldwide net earning share increase reflect operate profit percent equal share increase sale improvement nonamortization sfas net earning share exclude impact account improvement remain iprd merger cost iprd net favorable margin improvement prior year achieve despite adjustment cost associate global manu investment spending support cordis product line facture restructuring charge worldwide net earning operating profit include iprd associate acqui billion net earning share repre sition obtech medical inverness medical senting increase respectively technology terame worldwide net earning billion reflect increase worldwide net earning share provision taxis income equal share increase worldwide effective income tax rate net earning share exclude impact increase effective iprd net favorable adjustment cost associate tax rate year primarily global manufacturing restructuring charge tothe increase income subject tax merger cost worldwide net earning company nondeductible iprd charge refer footnote billion net earning share represent financial statement additional information increase respectively cash flow liquidity cash generate operation select borrowing pro vide major source fund growth business include work capital capital expenditure acquisition share repurchase dividend debt repayment cash current marketable security billion end compare billion end cash generate operation amount billion contractual obligation commitment cash generate operation company longterm contractual obligation primarily billion decrease primarily fund lease debt obligation satisfy obligation pension plan approximately million net company intend use cash operation follow current tax benefit change table summarize company contractual obligation time salary increase bonus pay employee aggregate maturity december note december february change enact detail result finalize order align compensation operate debt performance result change increase million dollar lease obligation approximately million cash flow operating activity payment bonus capital expenditure capital expenditure increase billion increase billion increase primarily expansion manufac ture facility support new exist product invest financial position capital resource ment support research investment information system business segment total asset return total asset increase billion bil share repurchase dividend lion consolidated assets yearend february company announce stock repur medical device diagnostic account chase program billion time limit pro pharmaceutical segment asset consumer gram program complete august segment asset general corporate asset million share repurchase aggregate price bil yearend consolidated asset lion addition stock repurchase program identifiable medical device diagnostic pharma company annual program repurchase share use ceutical segment respectively employee stock employee incentive plan consumer segment general corporate asset respectively company increase cash dividend net intangible asset increase rep theth consecutive year cash dividend pay resented total asset yearend net property pershare compare dividend share plant equipment increase billion share dividend represent total asset yearend distribute follow shareholder equity share end compare yearend decrease quarter thedecrease primarily billion stock repurchase second quarter program complete quarter financing marketrisk fourth quarter company use financial instrument manage impact total foreign exchange rate change cash flow accordingly company enter forward foreign exchange contract january board director declare regular protect value exist foreign currency asset liabili cash dividend share pay march tie hedge future foreign currency product cost gain shareholder record february company loss contract offset primarily effect expect continue practice pay regular cash dividend foreign exchange rate change underlie transaction appreciation dollar december market rate increase unrealized value company forward contract million conversely depreciation dollar december market rate decrease unrealized value company ward contract million scenario gain loss theforward contract offset effect eign exchange rate change underlie transaction company enter currency swap contract man matter age company exposure change currency exchange critical accounting policy estimate rate hedge foreign currency denominate asset lia management discussion analysis result operation bilitie impact change interest rate financial condition base company consolidate company interest rate sensitive financial instrument financial statement prepare accordance immaterial accounting principle generally accept company enter financial instrument preparation financial statement require management trading speculative purpose company estimate assumption affect amount policy enter contract party report revenue expense asset liability equivalent credit rating counterpartie relate disclosure actual result differ contract major financial institution estimate companys significant accounting policy company significant exposure coun describe note company believe terparty management believe risk loss remote understand certain key accounting policy estimate total unused credit available company approximate essential achieving insight company operat billion include billion credit commitment ing result financial condition key accounting policy billion uncommitted line bank worldwide estimate include revenue recognition accounting expire company shelf registration file income taxis legal self insurance contingency valuation security exchange commission enable long live asset assumption determine amount company issue billion unsecured debt security record pension employee benefit plan warrant purchase debt security medium accounting stock option term note mtn program mtns issue revenue recognition december company billion remain company recognize revenue product sale shelf registration company continue good ship deliver depend title company triple credit rating risk pass customer provision certain rebate sale total borrowing end bil incentive trade promotion coupon product return dis lion billion respectively net cash cash count customer provide reduction determin current marketable security net debt billion ing sale period relate sale record net cash cash current marketable security net provision large medicaid debt billion total debt represent total capi rebateprovision base estimate derive current tal shareholder equity total debt program requirement historical experience total capital period end december companyalso recognize service revenue receive material cash commitment summary bor copromotion certain product yearend december rowing find note revenue total revenue company believe operation comply include product sale material respect applicable environmental law regula tion company subsidiary party number income taxis proceeding bring comprehensive environmental income taxis record base amount refundable response compensation liability act commonly know payable current year include result differ superfund comparable state law relief ence gaap account tax reporting seek cost past future remediation record defer tax asset liability company feasible predict determine outcome proceed record defer tax asset liability base current tax ing opinion company proceeding regulation rate change tax law rate material adverse effect result operation cash affect defer tax asset liability record flow financial position company future management believe change estimate material effect company result operation cash flow financial position company intend continue reinv undistributed international earning expand international operation tax expense record tocover repatriation undistribute earning december december cumulative undis tribute international earning approximately billion billion respectively legal self insurance contingency fasb issue sfas accounting cost company record accrual contingency associate exit disposal activity effective include legal proceeding product liability case exit disposal activity initiate december theyarise normal course business accrual company adopt sfas quarter base management judgment probability expect material effect loss opinion legal counsel applicable actuari company result operation cash flow financial position ally determine estimate additionally company record november fasb issue fasb interpretation insurance receivable amount party insurer base fin guarantor accounting disclosure probability ofrecovery appropriate reserve requirement guarantee include indirect guarantee receivables record estimate amount indebtedness interpretation fasb statement collect party insurer rescission fasb interpretation fin clarifie requirement fasb statement long live intangible asset accounting contingency relate guarantor company assess change economic condition accounting disclosure issuance certain type strategic priority make assumption estimate guarantee disclosure requirement fin effec future cash flow evaluate value company fix tive financial statement interim annual period asset goodwill andother noncurrent asset assump end december adopt tion estimate change time company disclosure require yearend necessary forthe company record impairment charge provision initial recognition measurement effective employee benefitplan prospective basis guarantee issue modi company sponsor retirement pension plan fie december irrespective ofthe guarantor include define benefit define contribution termination yearend fin require issuance guarantee indemnity plan cover employee worldwide entity recognize liability fair value plan require assumption discount rate expect obligation assume guarantee company return plan asset expect salary increase health adoption fin expect material care cost trend rate note detail effect company result operation cash flow rate effect change rate companys financial position result operation january fasb issue fin consolidation variable interest entitiesan interpretation arb stock option address consolidation variable interest entity company elect use accounting principle board fin expand criterion consideration determine opinion accounting stock issue employee variable interest entity consolidated apb require compensation cost relate business entity require exist unconsolidated variable stock option record net income option interest entity include limited special grant stock option plan exercise purpose entity spe consolidate primary price equal market value underlie common stock beneficiary entity effectively disperse risk grant date statement financial accounting standard party involve interpretation applies immediately sfas accounting stockbase compensation variable interest entity create january transition disclosure amendment fasb statement variable interest entity enterprise obtain require pro forma disclosure net income earn interest date apply fiscal year inter ing share determine fair value method period begin june variable interest accounting stock option apply measure entity enterprise hold variable interest compensation cost note information acquire february adoption fin stock option expect material effect company result new accounting standard operation cash flow financial position june fasb issue sfas accounting asset retirement obligation company adopt standard effective fiscal year begin june expect material impact company result operation cash flow financial posi tion august fasb issue sfas accounting impairment disposal longlive asset effective quarter company adoption ofsfas material effect company result operation cash flow financial position june change price inflation expertise protein biology computational medicinal johnson johnson aware product set chemistry identify novel target rationally design small ting decade policymaker consumer molecule compound large market unmet medical business express concern rise cost need scio product natrecoris novel agent health care response concern johnson johnson approve congestive heart failure chf longstanding policy pricing product responsibly decade natrecoris recombinant form naturally forthe period united states weight occur protein secrete heart bodys average compound annual growth rate johnson johnson response chf drug significant advantage price increase health care product prescription exist therapy chf single common cause overthecounter drug hospital professional product hospitalization united states patient consumer price index cpi period principal focus scio research development inflation rate moderate part program small molecule inhibitor include world continue effect worldwide potential new treatment pain inflammatory disease economy consequently way company operate include advanced kinase inhibitor program face increase cost company strive maintain transaction expect close second quarter profit margin cost reduction program productivity company anticipate iprd charge improvement periodic price increase approximately million incur connection acquisition common stock marketprice company common stock list new york stock cautionary factor thatmay affectfuture result exchange symbol jnj composite market price annual report contain forwardlooke statement range johnson johnson common stock forwardlooke statement relate strictly historical orcurrent fact anticipate result base management plan subject uncertainty forwardlooke state ment identify use word like plan high low high low expect anticipate estimate word quarter ofsimilar mean conjunction thing second quarter discussion future operation financial performance quarter company strategy growth product development regulatory fourth quarter approval market position expenditure yearend close forwardlooke statement base current expecta subsequentevent tion future event company guarantee february johnson johnson announce forwardlooke statement accurate sign definitive agreement scios inc biopharmaceuti company believe reasonable expecta cal company market product cardiovascular dis tion assumption investor realize underly ease research project focus autoimmune disease ing assumption prove inaccurate unknown risk company acquire scios cash stock exchange uncertainty materialize actual result vary materially term agreement scio shareholder company expectation projection investor receive outstanding scios share value caution place undue reliance transaction anticipate closing date expect wardlooking statement furthermore company assume tobe approximately billion net cash anticipate obligation update forwardlooke statement acquire base scio approximately million fully result new information future event development dilute share outstanding company report year end december board directors johnson johnson scios file march contain give approval transaction subject exhibit discussion factor cause actual toclearance hartscottrodino antitrust improve result differ expectation prior file investor ment act transaction subject approval reference company report fis shareholder scio customary closing condition cal year end december company note scios biopharmaceutical company develop novel factor permit private security litigation reform treatment cardiovascular inflammatory disease act thecompany diseasebase technology platform integrate consolidated balance sheet johnson johnson subsidiaries december december dollar million share share datum note asset currentasset cash cash equivalent note marketable security note account receivable trade allowance doubtful account inventory note defer taxis income note prepay expense receivables total currentasset marketable security noncurrent note property plant equipment net note intangible asset net note defer taxis income note asset note total asset liability shareholdersequity currentliabilitie loan note payable note account payable accrue liability accrue salary wage commission taxis income total currentliabilitie longterm debt note defer tax liability note employee relate obligation note liability shareholdersequity prefer stockwithout par value authorize unissued share common stockpar value share note authorize share issue share note receivable employee stock ownership plan note accumulate comprehensive income note retain earning common stock hold treasury cost note total shareholdersequity total liability shareholdersequity note consolidated financial statement consolidate statement earning johnson johnson subsidiarie dollar million share figure note sale customer cost product sell gross profit selling marketing administrative expense research expense purchase inprocess research development note interest income interest expense net portion capitalize note income expense net earning provision taxis income provision taxis income note netearning basic netearning share note dilute netearning share note note consolidated financial statement consolidate statement equity johnson johnson subsidiary note receivable accumulate common employee stock treasury comprehensive retain stock ownership comprehensive issue stock dollar million note total income earning plan esop income balancejanuary net earning cash dividend pay employee stock compensation stock option plan conversion subordinate debenture repurchase common stock business combination comprehensive income net tax currency translation adjustment unrealize gainslosse security pension liability adjustment reclassification adjustment total comprehensive income note receivable esop balancedecember net earning cash dividend pay employee stock compensation stock option plan conversion subordinate debenture repurchase common stock business combination comprehensive income net tax currency translation adjustment unrealize gainslosse security gainslosse derivative hedge reclassification adjustment total comprehensive income note receivable esop balancedecember net earning cash dividend pay employee stock compensation stock option plan conversion subordinate debenture repurchase common stock comprehensive income net tax currency translation adjustment unrealize gainslosse security pension liability adjustment gainslosse derivative hedge reclassification adjustment total comprehensive income note receivable esop balancedecember note consolidated financial statement consolidate statement cash flow johnson johnson subsidiaries dollar million note cash flow operating activity net earning adjustment reconcile net earning cash flow depreciation amortization property intangible purchase inprocess research development defer tax provision account receivable reserve change asset liability net effect acquisition business increase account receivable increase decrease inventory increase account payable accrue liability increase decrease current noncurrent asset increase current noncurrent liability netcash flow operating activity cash flow invest activity addition property plant equipment proceed disposal asset acquisition business net cash acquire note purchase investment sale investment netcash investing activity cash flow financing activity dividend shareholder repurchase common stock proceed shortterm debt retirement shortterm debt proceed longterm debt retirement longterm debt proceed exercise stock option netcash financing activity effect exchange rate change cash cash equivalent decrease increase cash cash equivalent cash cash equivalent begin year note cash cash equivalentsend year note supplemental cash flow datum cash pay year interest income taxis supplemental schedule noncash investing financing activity treasury stock issue employee compensation stock option plan net cash proceed conversion debt acquisition business fair value asset acquire fair value liability assume treasury stock issue fair value net cash pay acquisition note consolidated financial statement note consolidated financial statement summary significantaccounte principle variable interest entity enterprise obtain interest date apply fiscal year principle consolidation interim period begin june variable interest financial statement include account johnson entity enterprise hold variable interest johnson subsidiary intercompany account acquire february adoption fin transaction eliminate expect material effect company result new accounting pronouncement operation cash flow financial position june financial accounting standard board cash equivalent fasb issue statement financial accounting standard company consider security maturity sfas accounting asset retirement obligation month purchase cash equivalent company adopt standard effective investment fiscal year begin june shortterm marketable security carry cost expect material impact company result approximate fair value longterm debt security operation cash flow financial position august company ability intent hold maturity thefasb issue sfas accounting impairment carry amortize cost approximate fair value disposal longlive asset effective investment classify availableforsale carry quarter company adoption sfas estimate fair value unrealize gain loss record material effect company result component accumulate comprehensive income operation cash flow financial position june management determine appropriate classification fasb issue sfas accounting cost associate investment debt equity security time purchase exit disposal activity effective exit reevaluate determination balance sheet disposal activity initiate december date company periodically review investment non company adoption sfas quarter marketable equity security impairment adjust expect material effect com investment fair value decline market value pany result ofoperation cash flow financial position deem temporary november fasb issue fasb interpretation fin guarantor accounting disclosure propertyplantand equipmentand depreciation requirement guarantee include indirect guarantee property plant equipment state cost indebtedness interpretation fasb statement companyutilize straightline method depreciation rescission fasb interpretation overthe estimate useful life asset fin clarifie requirement fasb statement building building equipment year accounting contingency relate guarantor land leasehold improvement year accounting disclosure issuance certain type machinery equipment year ofguarantee disclosure requirement fin effec tive financial statement interim annual period company capitalize certain computer software end december disclosure provision development cost incur connection develop implement disclosure require year orobtaine computer software internal use capitalize end provision initial recognition measure software cost amortize estimate useful life ment effective prospective basis guarantees ofthe software generally range year issue modify december irrespective company review longlive asset assess recoverabil guarantor yearend fin require issuance ity undiscounted cash flow necessary charge guarantee entity recognize aliability fair value impairment longlive asset record obligation assume guarantee com bywhich present value future cash flow pany adoption fin andis expect carrying value asset material effect company result operation revenue recognition cash flow financial position company recognize revenue product sale january fasb issue fin consolidation good ship deliver depend title variable interest entitiesan interpretation arb riskpasse customer provision certain rebate sale address consolidation variable interest entity fin incentive trade promotion product return discount expand criterion consideration determine customer provide reduction determine sale variable interest entity consolidate inthe period relate sale record business entity require exist unconsolidated variable interest entity include limited special sale incentive trade promotional allowance purpose entity spe consolidated primary company adopt emerge issue task force eitf beneficiary entity effectively disperse risk issue account consideration give vendor party involve interpretation apply immediately customer reseller vendor product effective decem variable interest entity create january ber prior period restate reclassify sale incentive trade promotional allowance sell value derivative recognize earning general administrative expense reduction offset current earning effect relate foreign sale cost sale assuch sale reduce mil currency asset liability lion million respectively cost designation cash flow hedge date product sell increase million million ofentere derivative contract inception deriva respectively tive expect highly effective change fair value derivative designate cash flow hedge shipping handle highly effective record accumulate shipping handling cost incur million comprehensive income underlie transaction affect million million respectively earning reclassify earning include sell marketing administrative account hedge transaction fair value forward expense revenue receive shipping exchange contract represent present value change handle immaterial period present forward exchange rate times notional inventory derivative fair value currency swap contract deter inventory state low cost market mine discount present future cash flow determine firstin firstout method currency exchange interest ratesprevaile market period currency exchange intangible asset express result dollar atthe current spot accordance sfas amortization foreign currency exchange rate record goodwill andor intangible asset deem ongoing basis company assess indefinite live acquisition complete june derivative continue highly effective offset change effective begin fiscal year accor cash flow hedge item derivative dance sfas company discontinue amor isno long expect highly effective hedge accounting tization relate exist goodwill indefinite live discontinue hedge ineffectiveness include intangible asset effect nonamortization good current period earning intangible asset approximately mil company document relationships hedge lion tax intangible asset finite item derivative overall risk management strategy useful life continue beamortize useful life include reason undertake hedge transaction sfas require goodwill nonamortizable enter derivative objective strategy intangible asset assess annually impairment minimize foreign currency exposure impact require initial assessment complete june company financial performance protect company impairment determine initial impairment cash flow adverse movement foreign exchange assessment update fourth quarter rate ensure appropriateness financial instrument impairment determine future impairment test manage enterprise risk associate finan perform fourth quarter annually cialinstitution financial instrument productliability effective january company adopt sfas accrual product liability claim record accounting derivative instrument hedge activi undiscounte basis probable liability tie amend sfas account certain incur liability reason derivative instrument certain hedging activity ably estimate base exist information accrual amendment fasb statement collectively refer adjust periodically additional information sfas sfas require derivative available receivables insurance recovery relate prod instrument record balance sheet fair value uct liability relate claim record undiscounted change fair value derivative record time value money basis probable period current earning comprehensive income recovery realize depend derivative designate hedge transaction depend type research development hedge transaction research development expense expense company use forward exchange contract manage incur upfront milestone payment exposure variability cash flow primarily relate party connection research development col foreign exchange rate change future intercompany laboration expense incur point product party purchase raw material denomi regulatory approval payment party subse nate foreign currency company use currency quent regulatory approval capitalize amortize swap manage currency risk primarily related borrow remain useful life relate product amount ing type derivative designate cash capitalize suchpayment include intangi flow hedge additionally company use forward exchange ble net accumulate amortization contract offset exposure certain foreign currency advertising asset liabilitie forward exchange contract cost associate advertising expense year designate hedge change fair incur advertising expense worldwide comprise television radio print medium internet require management estimate assump advertising billion billion tion affect amount report actual result billion differ estimate income taxis annual closing date company intend continue reinv undistributed company follow concept fiscal year end international earning expand international operation onthe sunday near end month december tax expense record cover normally fiscal year consist week repatriation ofsuch undistributed earning december year case fiscal year consist december cumulative week undistribute international earning approximately reclassification billion billion respectively certain prior year amount reclassify conform defer income taxis recognize tax consequence current year presentation temporary difference apply enact statutory tax rate applicable future year difference financial stock split report tax basis exist asset liability april board director declare stock split shareholder record close business netearning share issue additional share johnson basic earning share compute divide net income johnson common stock june share hold available common shareholder weight average record date share pershare datum number common share outstanding period dilute period present financial statement earning share reflect potential dilution adjust reflect stock split occur security contract issue common stock exercise convert common stock inventory stock option end inventory comprise december company stockbase dollar million employee compensation plan describe note raw material supply company account plan recognition good process measurement principle accounting principle board finish good opinion accounting stock issue employee andit relate interpretation compensation cost record net income stock option option grant plan exercise price equal market propertyplantand equipment value underlie common stock date grant end property plant equipment require sfas accounting stockbase cost accumulate depreciation compensationtransition disclosurean amendment dollar million offasb statement follow table show land land improvement estimate effect net income earning share building build equipment company apply fair value recognition provision machinery equipment sfas accounting stockbase compensation construction progress tostockbase employee compensation dollar million accumulate depreciation share datum net income report company capitalize interest expense cost ofconstruction facility equipment interest expense compensation capitalize million million expense million respectively pro forma depreciation expense include amortization capital ize interest billion billion earning share billion respectively basica report retirement disposal fix asset cost pro forma andrelate accumulate depreciation amortization dilutedas report eliminate asset accumulate depreciation pro forma account respectively difference net asset value proceed adjust toearning determine fair value base method awards net tax risk uncertaintie rental expense lease commitment preparation consolidated financial statement rental space vehicle manufacture equipment office conformity accounting principle generally accept datum processing equipment operating lease amount approximately million million company access substantial source fund million numerous bank worldwide total unused credit available approximate minimum rental payment require company approximate billion include billion operating lease initial remain noncancelable credit commitment billion uncommitted line lease term excess year december bank worldwide expire interest charge borrowing credit line agreement dollar million total base bid provide bank prime rate london interbank offer rate libor plus applicable mar gin commitment fee agreement material commitment capital lease significant company shelf registration file security exchange commission enable company issue employee relate obligation billion unsecured debt security warrant purchase end employee relate obligation debt security medium term note mtn program mtns issue december company dollar million billion remain shelf registration pension benefit long term debt include convertible subordinate post retirement benefit debenture issue alza prior merger post employment benefit johnson johnson defer compensation july alza complete private offering zero coupon convertible subordinated debenture current benefit payable issue price principal maturity december outstanding deben employee relate obligation ture total principal maturity billion yield maturity annum compute prepay employee relate obligation million semiannual bond equivalent basis periodic inter include asset consolidate balance sheet est payment term debenture holder entitle convert debenture approximately borrowing million share johnson johnson stock price component longterm debt follow share approximately share eff eff issue december voluntary conversion dollar millions rate rate note holder option holder debenture zero coupon repurchase company july convertible purchase price equal issue price plus accreted subordinateddebenture original issue discount purchase date company option elect deliver johnson johnson com zero coupon mon stock cash combination stock cash convertible event repurchase debenture company subordinateddebenture option redeem debenture july issue price plus accrete original issue debenture discount december december fair value base quote market value debenture note million million respectively debenture alza issue zero coupon convertible subordinated debenture price prin note cipal maturity december outstand eurodollar note ing debenture total principal maturity million yield maturity annum note computed semiannual bond equivalent basis note periodic interest payment term deben industrial revenue bond ture note holder entitle convert debenture principally approximately million share johnson johnson international stock price share approximately mil lion shares johnson johnson stock issue current portion december voluntary conversion note hold ers option holder debenture purchase company july july weight average effective rate purchase price equal issue price plus accreted represent dollar note issue japanese original issue discount purchase date december subsidiary convert fix rate yen note currency swap december fair value base quote market value debenture million weight average amortization period patent million respectively trademark intangible asset year shortterm borrowing current portion longterm year respectively amortization expense amortizable debtamounte billion end intangible asset forthe fiscal year end december borrowing comprise billion commercial paper millionpretax estimate amortization million local borrowing principally interna expense fivesucceeding year approximate tional subsidiary million pretax yearrespectively aggregate maturity longterm obligation commence income taxis provision taxis income consist dollar million dollar million currently payable tax intangible asset international taxis end gross net amount intangible asset defer dollar million taxis goodwillgross international taxis accumulate amortization goodwillnet trademark nonamortizablegross comparison income tax expense federal statutory accumulate amortization rate company effective trademark nonamortizablenet tax rate follow patent trademarksgross dollar million accumulate amortization international patent trademarksnet earning taxis intangiblesgross income accumulate amortization statutory taxis intangiblesnet tax rate statutory total intangible assetsgross puerto rico accumulate amortization ireland operation total intangible assetsnet research tax credit domestic state local goodwill december allocate segment international business follow subsidiary me dev exclude ireland dollar million consumer pharm diag total iprd goodwill net accumulate effective tax rate amortization december company subsidiary operate reclassification puerto rico tax incentive grant expire intangible net addition company subsidiary manufacturing ireland accumulate incentive tax rate effective year amortization acquisition translation goodwill december temporary difference carry forwards common stockstock option plan stock asfollows compensation agreement december company stockbase com defer tax defer tax pensation plan stock option plan com dollar million asset liability asset liability pany grant option employee employee relate issue share company common stock plus num obligation ber share available previous year depreciation issue share issue plan expire nondeductible orterminated exercised share outstanding intangible contract company international employee stock option plan nonemployee direc capitalize tax tor plan mitek cordis biosense gynecare centocor reserve liability innovasive device alzaand inverness stock option plan income report stock option generally expire year date tax purpose grant vest service period range miscellaneous year option grant current market price international date grant share available stock capitalize intangible option plan future grant base issue miscellaneous share year million share grant total deferred year year addition income taxis available share describe share avail able future grant plan million difference net defer tax income atthe end thebalance sheet net defer tax include summary status company stock option taxis income balance sheet plan december december december change year end international currency translation date ispresentedbelow weight translation subsidiary operate nonus dollar option average currency company determine local curren share thousand outstanding exercise price cie international subsidiary functional curren balance january cie highly inflationary economy option grant define compound cumulative rate option exercise inflation past year option canceledforfeite consolidate international subsidiary balance sheet cur balance december rency effect record component accumulate option grant comprehensive income equity account include result option exercise translate balance sheet asset liability current option canceledforfeite exchange rate locate highly inflationary balance december economy reflect operating result option grant analysis change foreign option exercise currency translation adjustment include note option canceledforfeite net currency transaction translation gain lossesinclude expense aftertax loss balance december million million million include option issue replace inverness option outstanding respectively grant prior acquisition year end december change accumulate comprehensive income inthe timing grant stock compensation option component comprehensive incomeloss consist employee december february follow change enact result finalize order total align compensation performance time unrealized gain accumulate foreign gain pension loss grant follow fiscal currency loss liability derivative comprehensive dollar million translation security adjustment hedge incomeloss average fair value option grant jan fair value change estimate blackschole option pricing model base dec weight average assumption change transition riskfree rate adjustment volatility net change expect life yrs yrs yrs hedge dividend yield transaction net follow table summarize stock option outstanding reclasse exercisable december net earning share thousand outstanding exercisable net average average exercise average exercise exercise change price range option lifea price option price dec change net change hedging transaction net reclasse net earning net aaverage contractual life remain year change dec stock option exercisable december december option average exercise total comprehensive income include price option average exercise price reclassification adjustment gain million realize respectively sale equity security associate taxexpense million total comprehensive income include reclassification adjustment gain million real segment business geographic area ize sale equity security associate tax information segment business expense million total comprehensive geographic area income include reclassification adjustment gain mil lion associated tax expenseof million tax effect unrealize gainslosses equity security benefit million expense million expense million tax effect gainslosse derivative hedge benefit million andan expense million note additional information relate derivative hedge currency translation adjustment currently adjust income taxis relate permanent investment nonus subsidiary retirementand pension plan fund sufficient provide accrue benefit international subsidiary plan fund deposit company sponsor retirement pension trustee annuity purchase group contract plansinclude define benefit define contribution reserve provide termination indemnity plan cover employee certain country united states fund worldwide company provide postretirement pension plan common practice funding provide benefit primarily health care domestic retire economic benefit consequently company pension employee dependent plan fund international employee cover government company fund retiree health care benefit sponsor program cost companyis advance right modify plan thefuture significant net periodic benefit cost company define benefit retirement plan benefit primarily base retirement plan benefit plan employee compensation year include follow component retirement number year service com pany objective fund domestic plan accumulate retirement plan benefit plan dollar million service cost interest cost expect return plan asset amortization prior service cost amortization net transition asset recognize actuarial gain curtailment settlement net periodic benefit cost net periodic income cost attributable domestic retire ment plan million million million follow table provide weightedaverage assump tion develop net periodic benefit cost actuar ial present value project benefit obligation retirement plan benefit plan domestic benefitplan weight average discount rate expect longterm rate return plan asset rate increase compensation level international benefitplans weight average discount rate expect longterm rate return plan asset rate increase compensation level health care cost trends united states project plan asset consist primarily list common stock annual rate individual grade nonus equity fix income investment fair year effect change value johnson johnson common stock plan asset assume cost trend accumulate postretirement million december benefit obligation atthe end million increase million decrease effect service interest costcomponent net periodic postretirement benefit cost million increase million decrease follow table set forth change benefit obliga tion change plan asset yearend company define benefit retirement plan benefit plan dollar million retirement plan benefit plan change benefitobligation benefit obligationbeginning year service cost interest cost plan participant contribution amendment actuarial loss divestiture acquisition curtailment settlement total benefit pay effect exchange rate benefit obligationend year change plan asset plan asset fair valuebeginne year actual return plan asset company contribution plan participant contribution divestiture benefit pay plan asset effect exchange rate plan asset fair valueend year amount recognize company balance sheetconsistof follow retirement plan benefit plan dollar million plan asset project benefit obligation unrecognized actuarial lossesgain unrecognized prior service cost unrecognized net transition asset total recognize consolidated balance sheet book reserve prepaid benefit intangible asset accumulate comprehensive income total recognize consolidated balance sheet minimum pension liability adjustment require minimum pension liability adjustment actuarial present value accumulate benefit abo exceed million million respectively relate primarily fair value plan asset accrue pension liability plan outside plan accumulate benefitobligation excess plan asset consistof follow retirement plan benefit plan dollar million accumulate benefit obligation project benefit obligation plan asset fair value marketable security december december net unrealize unrealized estimate net unrealize unrealized estimate dollar million cost gain loss fair value cost gain loss fair value money market fund commercial paper time deposit government security obligation asset back security bank note corporate debt security total current marketable security government security asset back security bank note corporate debt security investment hold trust total noncurrent marketable security current marketable security include billion billion classified cash equivalent balance sheet december december respectively financial instrument concentration creditrisk company invest excess cash deposit effective january company adopt sfas withmajor bank world high quality require derivative instrument record money market instrument refer note additional thebalance sheet fair value information company policy make investment december balance defer net loss onlywith commercial institution derivative include accumulate comprehensive orequivalent credit rating investment generally income million aftertax additional information mature month company incur note company expect related loss million reclassify earning month result transaction expect occur period ultimately realize saving plan earning differ foreign exchange rate change realize company voluntary saving plan design gain loss ultimately determine byactual exchange enhance exist retirement program cover eligible rate maturity derivative transaction employee company match percentage party cause accumulate compre employee contribution consistent provision hensive income affect net earning maximum length plan heshe eligible oftime company hedging month salary plan onethird company match year end december net impact pay company stock employee stock ownership hedge ineffectiveness company financial statement plan esop establish esop company insignificant year end december loan million esop trust purchase share company record net gain million tax company stock open market exchange com income expense net category consolidated pany receive note balance record statement earning represent impact discontinu reduction shareholder equity ance cash flow hedge probable origi total contribution plan million nally forecast transaction occur end million million originally specify time period refer note disclosure movement accumulate comprehensive income merger acquisition account purchase method accordingly result operation include accompany certain business acquire million cash consolidated financial statement respective date liability assume million assume acquisition acquisition account purchase method acquisition include inverness medical technol accordingly result operation include ogy supplier lifescan electrochemical product accompany consolidated financial statement blood glucose monitoring follow spinoff non respective date acquisition diabete business heartport company develop acquisition include tibotecvirco manufacture product invasive open chest mini privatelyheld biopharmaceutical company focus devel mally invasive heart operation include stop heart ope antiviral treatment micro type system inc beat heart procedure terame inc earlystage manufacturer reagent supplier distribute instru medical device company develop endovascular ment know idmicro type systemtmand obtech stentgraft system minimally invasive treatment medical privatelyheld company market abdominal aortic aneurysm peripheral occlusive disease adjustable gastric band treatment morbid obesity babycenter llc internet content commerce com excess purchase price estimate fair value pany devoted support community expectant tangible asset acquire entity amount new mother viactivproduct line chewable cal million hasbeen allocate identifiable intangible cium supplement mead johnson nutritionals divi goodwill addition approximately million sion bristolmyer squibb identify value inprocess research development inverness medical technology acquire enhance iprd associate tibotecvirco obtech control primary supplier lifescan blood glucose mon medical acquisition itore product allow achievement opera iprd charge related tibotecvirco tional synergies acquisition provide key technology million associate early stage hiv compound development future product value iprd calculate assistance approximately million identify value party appraiser cash flow projection discount iprd associate inverness medical technology risk inherent project probability suc teramed inc acquisition iprd charge primar cess factor range discount rate ily relate inverness project minimally invasive testing iprd charge relate obtech medical continuous monitor insulin delivery value million associate development current iprd calculate assistance party swedish adjustable gastric band sagb use united appraiser cash flow projection discount risk state development generation technology inherent project probability success factor platform value iprd calculate range discount rate assistance party appraiser cash flow projec certain business acquire million tion discount risk inherent project acquisition account purchase probability success factor discount rate method accordingly result operation pro forma information provide impact include accompany consolidated financial state acquisition material effect com ment respective date acquisition pany result operation cash flow financial position acquisition include crescendo company june johnson johnson alza cor form alza purpose select develop poration alza complete merger commercialize human pharmaceutical product innovasive company transaction account pooling device company manufacture sell device ofinterest alza approximately million share sport medicine surgery soft tissue injury atrionix inc stand million fully dilute basis thatwere adevelopment stage company primary product exchange approximately million share ofjohnson pulmonary ablation catheter treatment atrial fibril johnson common stock dilute basis whenadjuste lation medtrex company develop manufacture stock option convertible debt number johnson electrosurgical generator disposable product johnson share issue total approximately million josephaspirin business iprd writeoff associated holders alza common stock receive share atrionix inc alzas crescendo acquisition johnson johnson common stock value share million iprd charge primarily relate atrionix alza researchbased pharmaceutical company project design catheter system lead drug delivery technology company apply procedure block electrical impulse originate pul delivery technology develop pharmaceutical product monary vein cause atrial fibrillation value withenhance therapeutic value johnson johnson iprd calculate assistance party affiliate portfolio world lead appraiser cash flow projection discount risk pharmaceutical company inherent project discount rate certain business acquire billion divestiture material billion cash liability assume effecton company result operation cash flow million share company common stock issue financial position treasury value billion acquisition legal proceeding respect propulsidaction janssen company dispute claim company involve numerous product liability case lawsuit vigorously defend united states concern adverse reaction judgment settlement appropriate janssen drugs medical device damage claim substan company believe adequate selfinsurance tial company confident adequacy reserve commercially available excess insurance warning instruction use accompany prod respect case communication company uct feasible predict ultimate outcome litiga excess insurance carrier raise certain defense tion company believe liability result liability policy opinion com case substantially cover reserve pany defense pro forma lack substance establish selfinsurance program commer carrier honor obligation policy cially available excess liability insurance company ortho biotech subsidiary party group case company concern arbitration proceeding file amgen ortho janssen pharmaceutica product propulsid biotechs licensor nondialysis right procrit draw general sale restrict limited use amgen seek terminate ortho biotechs license wake publicity event numerous lawsuit right collect substantial damage base allege delib file janssen wholly own erate procritsale ortho biotech early subsidiary company company amgen reserve dialysis market october propulsidin state federal court country thearbitrator issue decision reject amgen request approximately case currently pende toterminate license find material breach include theclaim approximately plaintiff license arbitrator find conduct ortho recently file mississippi avoid application tort biotech early subsequently halt reform legislation effective january case byortho biotech amount nonmaterial breach likely file mississippi serve license award amgen million damage active case individual allege die thecompany expense quarter amgen use propulsid action seek substantial compen hadsought billion damage january satory punitive damage accuse janssen arbitrator rule amgen prevail party company inadequately testing warning arbitration entitling award reasonable attorney fee drug effect promote offlabel use cost amgen submit application forfee promotion addition janssen company enter cost company expense million fourth agreement plaintiff counsel halting run quarter connection outstanding claim ne statute limitation respect potential patent infringement action try delaware federal claim significant number individual attor court late cordis corporation subsidiary johnson ney evaluate sue janssen company johnson obtain verdict infringement patent valid behalf ity damage awards boston scientific corporation september plaintiffs rankin case medtronic ave inc base number cordis coro comprise claim propulsidplaintiff go nary stent patent december jury dam trial state court claiborne county mississippi jury age action boston scientific return verdict return compensatory damage verdict plaintiff million december jury medtronic million total million trial ave action return verdict million sums rep judge dismiss claim punitive damage resent lose profit reasonable royalty damage compen march trial judge reduce verdict total sate cordis infringement include pre post million deny motion janssen com judgment interest february hearing hold pany new trial janssen company believe claim boston scientific medtronic ave patent verdict reduce insupportable issue unenforceable owe allege inequitable con appeal view janssen company proof duct patent office march trial demonstrate plaintiff injure district judge issue post trial ruling confirm propulsidand basis liability exist validity enforceability main cordis stent patent april state court judge new jersey deny claim find certain cordis patent unenforceable plaintiff motion certify national class propulsid district judge grant boston scientific new user purpose medical monitoring refund trialon liability damage vacate verdict cost purchase propulsid effort appeal rule medtronic ave legal ground appeal federal circuit deny june federal judge preside court appeal underway propulsidmultidistrict litigation new orleans products johnson johnson operate com louisiana similarly deny plaintiff motion certify panie subject patent lawsuit national class propulsiduser plaintiff multi potentially affect ability operate company sell district litigation say preserve right product require payment past damage future appeal ruling complaint file janssen royalty respect patent challenge generic phar company include class action allegation maceutical firm result introduction generic version basis future attempt class certify product question ensue loss market share earning share follow patent lawsuit concern important product follow reconciliation basic net earning share johnson johnson operate companiesmedtronic diluted net earning share year end decem ave cordis corporation action file april ber december december infederal court texas assert certain patent own share millions medtronicave cordis bxvelocitytmstent basic earning share isalso stent structure cyphertmdrug elute average share product trial date set action ortho phar outstandingbasic maceutical barr laboratories inc pende federal court potential share new jersey action file june involve barr exercisable effort invalidate orthos patent cover ortho tri stock option plan cyclenoral contraceptive product trial share repurchase schedule case orthomcneil daiichi inc mylan treasury stock method laboratory andorthomcneil daiichi inc teva phar convertible debt share maceutical matter file febru ary federal court west virginia second adjusted average share june federal court new jersey concern effort outstandingdilute mylan teva invalidate establish noninfringement dilute earning share patent cover levaquinlevofloxacin tablet patent dilute earning share calculation include dilution own daiichi exclusively license orthomcneil effect convertible debt decrease interest expense mylan case trial hasbeen set late trial date million million million tax year set teva matter janssen alza mylan labo respectively ratorie action file federal district court vermont dilute earning share exclude million share february concern mylan effort invalidate assert option year million noninfringement ofalzas patent cover duragesic share ofoption year exercise price product trial likely spring respect ofthese option great average market matter thejohnson johnson operate com valueresulte antidilutive effect dilute earning pany involve vigorously defend validity assert share infringement itsown licensors patent product accuse infringe patent hold defend ing claim capital treasury stock company involve number patent change treasury stock trademark lawsuit incidental business treasury stock ultimate legal financial liability company mlla ber oin rio sand share respect claim lawsuit proceeding refer balance january estimate certainty employee compensation stock opinion management base examination option plan matter experience date discussion counsel conversion subordinate debenture ultimate outcome legal proceeding net liabili repurchase common stock tie accrue company consolidate balance business combination sheet expect material adverse effect company consolidate financial position reso balance december lution report period matter employee compensation stock significant impact company result option plan operation period conversion subordinate debenture repurchase common stock business combination balance december employee compensation stock option plan conversion subordinate debenture repurchase common stock balance december share common stock authorize issue share end select quarterly financial datum unaudite select unaudited quarterly financial datum year summarize second fourth second fourth dollar million share amount quarter quarter quarter quarter quarter quarter quarter quarter segment sale customer consumer pharmaceutical med device diagnostic total sale gross profit earning provision taxis income net earning basic net earning share dilute net earning share second quarter include tax charge million relate inprocess research development iprd cost quarter include tax charge million relate amgen arbitration settlement fourth quarter include tax charge million relate amgen legal fee second quarter include tax charge million relate alza merger cost quarter include tax charge million relate alza merger cost fourth quarter include tax charge million relate iprd cost fourth quarter include tax charge million relate lifescan class action settlement subsequentevent scios biopharmaceutical company develop novel treatment cardiovascular inflammatory disease february johnson johnson announce thecompany diseasebase technology platform integrate sign definitive agreement scios inc biopharmaceu expertise protein biology computational medicinal tical company market product cardiovascular dis chemistry identify novel target rationally design small ease research project focus autoimmune disease molecule compound large market unmet medical company acquire scios cash stock exchange need scios product natrecoris recombinant form term agreement scio shareholder anaturally occur protein secrete heart receive outstanding scios share value thebodys response congestive heart failure chf drug transaction anticipate closing date expect significant advantage exist therapy tobe approximately billion net cash anticipate chf single common cause hospitalization acquire base scio approximately million fully unite states patient dilute share outstanding principal focus scio research development board directors johnson johnson scios program small molecule inhibitor include havegiven approval transaction subject potential new treatment pain inflammatory disease toclearance hartscottrodino antitrust improve include advanced kinase inhibitor program ment act transaction subject approval transaction expect close second quarter shareholder scio customary closing condition independent auditor report shareholder board directors johnson johnson opinion accompany consolidated balance sheet relate consolidated statement earning consoli date statement equity consolidate statement cash flow present fairly material respect financial position johnson johnson subsidiaries december december result operation cash flow year inthe period end december conformity accounting principle generally accept united states america financial statement responsibility company management responsibility express opinion financial statement base audit conduct audits statement accordance auditing standard generally accept united states america require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement assess accounting principle significant esti mate management evaluate overall finan cial statement presentation believe audits provide reasonable basis opinion discuss note financial statement company adopt statement financial accounting standard goodwill intangible asset effective december new york new york january note date isfebruary segment business johnson johnson subsidiarie sale customer dollar million consumerdomestic international total pharmaceuticaldomestic international total medical device diagnosticsdomestic international total worldwide total operating profit identifiable asset dollar million consumer pharmaceutical medical device diagnostic segment total expense allocate segment general corporate worldwide total addition property depreciation plant equipment amortization dollar million consumer pharmaceutical medical device diagnostic segment total general corporate worldwide total geographic area sale customer longlive asset dollar millions united states europe western hemisphere exclude asiapacific africa segment total general corporate non longlived asset worldwide total management discussion analysis page description segment company business export sale intersegment sale significant sale distributor account total revenue saleswere concentrated pharmaceutical segment sale procriteprexaccounte total company revenue respectively amount allocate segment include interest incomeexpense minority interest general corporate income expense general corporate include cash marketable security include million inprocess research development iprd million million amgen cost pharmaceutical segment million iprd medical device diagnostic segment include million alza merger cost pharmaceutical segment million iprd million ofclass action settlement medical device diagnostic segment include restructure gain million consumer segment million million iprd charge net restructuring gain pharmaceutical medical device diagnostic segment respectively summary operation statistical data johnson johnson subsidiarie dollar million share figure sale customersdomestic sale customersinternational total sale cost product sell sell marketing administrative expense research expense purchase inprocess research development interest income interest expense net portion capitalize income expense net earning provision taxis income provision taxis income earning cumulative effect accounting change cumulative effect accounting change net tax netearning percent sale customer dilute net earning share common stock percent return average shareholder equity percentincrease decrease previous year sale customer dilute net earning share supplementary expense datum cost material service total employment cost depreciation amortization maintenance repair total tax expense supplementary balance sheetdata property plant equipment net addition property plant equipment total asset longterm debt operate cash flow common stock information dividend pay share shareholder equity share market price share yearend close average share outstanding millionsbasic diluted employee thousand adjust reflect twoforone stock split exclude cumulative effect accounting change million earning percent sale customer accounting change earning share accounting change earning percent return average shareholder equity accounting change dilute net earning share percent increase prior year accounting change dilute net earning share increase prior year exclude inprocess research development iprd merger restructuring cost dilute net earning share increase prior year diluted net earning share increase prior year diluted net earning share increase prior year diluted net earning share increase prior year diluted net earning share increase prior year cost product sell include million inventory writeoff restructure percent return average shareholder equity earning percent sale customer dilute net earning share increase prior year period adjust include effect alza merger net interest income include cost material service category include taxis income payroll property business taxis principal global affiliate advanced sterilization product division ethicon inc develop manufacture market range sterilization system base patented low temperature hydrogen peroxide gas plasma process sterilizingdisinfecte solution sterradsterilization system safe fast environmentally friendly effective broad range medical product health care facility cidexopa solution fast effective method disinfect wide wwwsterradcom range instrument endoscope alzacorporation pioneer continue lead development drug deliverybased pharmaceuticals johnson johnson company enhance health care million patient worldwide alzaalso partner lead pharmaceutical biotechnology company develop product address unmet patient need precisely control wwwalzacom target timing dose therapeutic compound babycenter llc lead online pregnancy parenting resource reach million new mom month web site babycentercom parentcentercom compa provide awardwinne health child development parenting information customize womans stage pregnancy child age babycenter offer online baby store wwwbabycentercom thrive online community centocor inc lead fully integrate biopharmaceutical biotechnology company special ize development commercialization therapeutic product meet critical human health care need world leader monoclonal antibody technology manufacturing centocor manufacture product include remicadeinfliximab treatment rheumatoid arthri tis crohns disease reoproabciximab use percutaneous coronary intervention wwwcentocorcom retavasereteplase clot buster administer heart attack cordis corporation global leader develop marketing device circulatory disease management include stent balloon catheter treat cardiovascular disease relate condition product market clinical application main division cordis cardiology coronary application cordis endovascular peripheral application cordi neurovascular neurological application biosense webster electrophysiology wwwcordiscom medical sensor technology endocardial procedure depuy inc develop market product depuy ace acrome codmanand mitekbrands depuy depuy ace provide product reconstruct damage diseased joint repair reconstruct traumatic skeletal injury acrome facilitate fusion element spine correction spinal deformity repair bone fracture codman provide surgical treatment central nervous system disorder wide range product hydrocephalic shunt valve system implantable drug pump micro surgical instrumentation mitek product sport medicine line offer innovative device wwwdepuycom treatment soft tissue injury ejnj llc catalyst accelerate adoption ebusiness identification incubation development new webenable health care business model increase long term growth potential ethicon inc global leader develop marketing product surgery area wound care wound management women health cardiovascular surgery advanced wound care treatment product market division ethiconproduct offer device facilitate precise wound closure tissue repair cardiovationspioneer mini mallyinvasive surgical device help restore improve cardiac health gynecareoffer minimallyinvasive solution gynecological health problem johnson johnson wound management offer complete line innovative product hemostasis tissue regeneration wwwethiconinccom advanced wound care ethicon endosurgery inc develop market broad portfolio advance surgical instru ment invasive traditional surgery line safety catheter vascular access mission help physician world transform patient care innova tion company focus design innovative procedureenabling device interventional diagnosis treatment disease condition area general thoracic wwwethiconendocom bariatric surgery breast disease gynecology urology greiter develop produce line elegant sunscreen aftersun product combine sun protection special moisturizer product sell europe market independence technology llc market product service increase independence people disability product include independenceiglidemanual assist wheelchair independencemaxproseat cushion independenceibotmobility system expect approve wwwindependencenowcom janssencilag company produce market broad range pharmaceutical product mainly discover andor develop johnson johnson pharmaceutical research development llc lead product include eprexerypohematology risperdalpsychia try sporanoxdermatologyfungal infection duragesicdurogesicpain management wwwjanssencilagcom topamaxepilepsy parietaciphexgastroenterology reminylalzheimer disease janssen pharmaceutica product produce market prescription medication thera peutic area central nervous system disorder gastrointestinal health pain management treatment fungal infection lead product include risperdalrisperidone antipsychot aciphexrabeprazole sodium proton pump inhibitor duragesicfentanyl transdermal system skin patch treatment moderate severe pain sporanoxitraconazole wwwjanssencom antifungal reminylgalantamine hydrobromide alzheimer disease primary business johnson johnson consumer product company baby care wound care skin care company wide range product include familiar line baby child care product complete line family aid home health care productsskin care product cleanser astringent moisturizer acne treatment body powder wwwjohnsonsbabycom johnson johnson development corporation make equity investment earlystage venture young publiclytrade health care company promise new technology development portfolio company include field pharmaceutical biotechnology medical surgical device health care information technology diagnostic consumer product johnson johnson gateway llc develop manage webbase resource information create health care professional johnson johnson medical device diagnostic company access global internet destination product information clinical content professional education patient material country ecommerce transaction wwwjnjgatewaycom inquiry capabilities johnson johnson health care systems inc provide national manage care government large hospital customer single point contact product johnson johnson domestic company addition customer account management company offer business support service include contract management supply chain electronic business resource wwwjjhcscom health fitness service employer johnson johnson merck consumer pharmaceutical joint venture form develop market broad range nonprescription product derive primarily merck inc prescription medicine product license acquire outside source current product include pepcidac acid controller prevention relief heartburn acid indigestion pepcidcomplete combination acid controller antacid wwwjnjmerckcom mylantaantacid lead line antacidantigas product liquid solid form johnson johnson pharmaceutical research development llc conduct research development achieve regulatory approval product psychiatry gastroenterology oncology antiinfective central nervous system diabete hematology immunologyinflammation women health wound healing wwwjnjpharmarndcom johnson johnson sales logistics company division johnson johnson consumer company inc provide sale marketing logistical service retail customer behalf domestic consumer operating company represent single point contact customer customerfocuse selling team customer service distribution retail merchandi e professional detailing additionally slc provide leadership emerge global customer base area transportation enterprisewide system business process global customer development lifescan inc dedicate improve quality life people diabete develop manufacturing marketing wide range blood glucose monitoring system software use individual diabete health care institution lifescan brand include onetouchbrand consumer product consist portable electronic meter disposable reagent test strip provide accurate painful blood glucose reading surestep wwwlifescancom brand institutional system mcneil consumer specialty pharmaceutical division mcneilppc inc market range overthecounter prescription pharmaceutical include complete line tylenol acetaminophen motrinib ibuprofen product adult child mcneil otc brand include imodiumad antidiarrheal josephadult regimen aspirin nizoral shampoo prescription product include concertamethylphenidate hcl attention deficit hyperactivity disorder floxinotic ofloxacin otic solution ear infection wwwtylenolcom mcneil comarkets daiichi pharmaceutical corp mcneil nutritionals division mcneilppc inc market innovative nutritional product dietary alternative major franchise include benecolcholesterollowere food supplement lactaidproduct enable lactoseintolerant consumer enjoy dairy food splendasucralose calorie sweetener broadbase application viactiv wwwbenecolcom calcium supplementation johnson johnson network computing service provide broad range network compute technology product service solution johnson johnson operate com panie world group provide leadership optimization enterprise information management infrastructure development emerge infra structure technology create new business opportunity internal customer neutrogena corporation develop manufacture market premium high quality skin hair care product sell worldwide recommend medical professionalsthe prod uct line include bar liquid cleanser shampoo hand cream body lotion facial moisturizer bath preparation cosmetic hair skin care product orthoneutrogena group company market skin hair care product recommend wwwneutrogenacom prescribe dermatologist noramco inc produce variety active pharmaceutical ingredient major world wide producer medicinal analgesic pharmaceutical intermediate synthetic fine organic wwwnoramcocom chemical produce monomer polymer pharmaceutical medical devices ortho biotech products worldwide affiliate market procritepoetin alfa know eprexand erypooutside treat anemia associate specific disease company market orthocloneoktmuromonabcd monoclonal antibody reverse rejection transplanted organ sporanoxitraconazole difficult totreat lifethreatening fungal infection leustatincladribine hairy cell leukemia duragesicfentanyl transdermal system moderate severe chronic pain cancer patient ortho biotech market doxildoxorubicin hcl liposome injection wwworthobiotechcom ovarian cancer kaposis sarcoma orthoclinical diagnostic inc provide professional diagnostic product hospital laboratory commercial clinical laboratory blood donor center product include reagent blood transfusion blood screen reagent instrument system clinical chemistry rhogam injectable drug prevent hemolytic disease newborn wwworthoclinicalcom orthomcneil pharmaceutical inc provide prescription drug follow category women health analgesic antiinfective antiepileptics urology company pioneer leader area reproductive health lead contraceptive product include ortho tricyclenlo norgestimateethinyl estradiol ortho evra norelgestrominethinyl estradiol weekly contraceptive patch lead product include ultracettramadol hci pain medication levaquinlevofloxacin antibiotic ditropan xloxybutynin chloride overactive bladder elmironpentosan polysulfate wwworthomcneilcom sodium interstitial cystitis topamaxtopiramate antiepilepsy medication personal product company division mcneilppc inc develop produce market innovative oral health women health sanitary protection product leader oral health market line reachfloss actrinse reachtoothbrush product personal product leader women health product monistatvaginal yeast cure kypersonal lubricant uristaturinary pain relief tablet vaginal contraceptive companys comprehensive line sanitary product include carefreepantiliner wwwitsmybodycom tampon stayfreemaxi pad pharmaceutical source group americas division orthomcneil pharmaceutical inc integrate johnson johnson pharmaceutical operation quality assurance organization america enhance supply chain performance rocis line product care sensitive skin include lotion cosmetic cream face body anda sun protection line wwwroccom spectacle lens group division johnson johnson vision care inc design develop manufacture market innovative spectacle lense line product newly patent innovation progressive addition lens market design meet need today presbyopes therakos inc specialize extracorporeal cellbase therapy prevention treatment immunemediate neoplastic disease substantial unmet medical need therakos proprietary procedure photopheresis currently approve successfully physician palliative treatment skin manifestation cutaneous tcell lymphoma additional research way treatment autoimmune disease complication wwwtherakoscom transplantation improve delivery therapy vistakon division johnson johnson vision care inc world lead disposable contact lens brand acuvue acuvue surevuebrand marketleade spherical brand day acuvuebrand topselle daily disposable product worldwide acuvue brand bifocal contact lens lead disposable product presbyope acuvuebrand toric unique lens people astigmatism new acuvue coloursbrand contact lense wwwjnjvisioncom launch world offer exceptional comfort handle seven naturallooke color worldwide family company united states gynecare lifescaninc somerville new jersey milpitas california advanced sterilization product schwartz phd worldwide president luther president irvine california corsaro president johnson johnson wound management mcneil consumer specialty pharmaceutical somerville new jersey alza corporation division mcneilppc inc wildman worldwide president mountain view california fort washington pennsylvania rosen president ethicon endosurgeryinc mccomb president cincinnati ohio babycenterllc mcneil nutritional salerno president san francisco california division mcneilppc inc baker general manager independence technologyllc fort washington pennsylvania warren new jersey watts president centocorinc butel president malvern pennsylvania neutrogena corporation vernon president janssen pharmaceutica productslp los angeles california titusville new jersey mcnamara global president cordis corporation gorsky president cardiology orthoneutrogena miami florida johnson johnson skillman new jersey odwyer worldwide president consumer product company altomari general manager division johnson johnson endovascular consumer company inc noramcoinc warren new jersey skillman new jersey athens georgia zilm worldwide president dagostino global president perkin president skin care biosense webster inc ortho biotech productslp mccoy president diamond bar california bridgewater new jersey babykids wind care lebeau worldwide president reedy president johnson johnson orthoclinical diagnosticsinc neurovascular developmentcorporation raritan new jersey miami florida new brunswick new jersey rochester new york lebeau worldwide president holveck president burzik president depuy johnson johnson gatewayllc orthomcneil pharmaceuticalinc depuy orthopaedics inc piscataway new jersey raritan new jersey warsaw indiana lee worldwide vice president fischer president sidow worldwide president johnson johnson health care systemsinc personal product company depuy acrome inc piscataway new jersey division mcneilppc inc raynham massachusetts barstad president acute care skillman new jersey fender worldwide president martin president sneed global president manage markets codman shurtleff inc pharmaceutical sourcing group johnson johnsonmerck raynham massachusetts americas consumer pharmaceutical kashuba worldwide president raritan new jersey fort washington pennsylvania austin president miller president mitek product westwood massachusetts johnson johnson network spectacle lens group johnson johnson vision careinc bianchi worldwide president computing services roanoke virginia raritan new jersey ejnjllc hogan president shea president north brunswick new jersey therakosinc hammitt president johnson johnson pharmaceutical research developmentllc exton pennsylvania ethiconinc raritan new jersey davis president cardiovations weisman president vistakon division somerville new jersey johnson johnson vision careinc coradini worldwide president johnson johnson sales logistics company jacksonville florida ethicon products division johnson johnson casey group president somerville new jersey consumer company inc global franchise america holland worldwide president new brunswick new jersey colleran president canada mexico czech republic janssencilag farmaceutica janssencilag janssenortho inc prague north york ontario mexico city johnson johnson spol sro johnson johnson inc johnson johnson mexico prague montreal quebec denmark mexico city johnson johnson medical products janssencilag markham ontario johnson johnson medical mexico birkerod england lifescan canada ltd mexico city cordis limited burnaby british columbia panama south ascot mcneil consumer healthcare canada johnson johnson central america depuy international limited guelph ontario panama city leed ortho biotech peru ethicon endosurgery toronto ontario johnson johnson del peru bracknell lima orthoclinical diagnostics mississauga ontario puerto rico janssencilag limited johnson johnson caribbean high wycombe vistakon caguas johnson johnson limited markham ontario johnson johnson medical caribbean maidenhead caguas latin america lifescan uruguay high wycombe argentina johnson johnson uruguay janssencilag farmaceutica montevideo ortho biotech buenos aire high wycombe venezuela johnson johnson janssencilag farmaceutica orthoclinical diagnostic argentina cel caracas amersham buenos aires johnson johnson venezuela vistakon europe johnson johnson medical caracas bracknell buenos aire finland brazil europe janssencilag janssencilag farmaceutica ltda espoo austria paulo janssencilag gmbh france johnson johnson indstria vienna cordis issylesmoulineaux comrcio ltda johnson johnson gmbh paulo hallein depuy france lyon johnson johnson professional johnson johnson medical gmbh products ltda vienna ethicon paulo issylesmoulineaux belgium chile janssencilag ethicon endosurgery johnson johnson chile antwerp issylesmoulineaux santiago colombia janssen pharmaceutica janssencilag janssencilag farmaceutica beerse issylesmoulineaux bogota johnson johnson consumer benelux johnson johnson johnson johnson colombia brussels consumer france sas cali issylesmoulineaux lifescan benelux johnson johnson medical colombia beerse lifescan bogota issylesmoulineaux tibotecvirco mechelen ortho biotech depuy italy srl scotland issylesmoulineaux milan ethicon limited edinburgh orthoclinical diagnostic ethicon spa issylesmoulineaux rome slovenia johnson johnson germany ethicon endosurgery ljubljana cordis gmbh rome langenfeld spain janssencilag spa janssencilag depuy orthopdie gmbh milan madrid sulzbach johnson johnson spa johnson johnson ethicon gmbh rome madrid norderstedt lifescan johnson johnson medical ethicon endosurgery milan madrid europe gmbh norderstedt ortho biotech johnson johnsonmerck europe milan madrid janssencilag gmbh rosellen orthoclinical lifescan diagnostic spa madrid johnson johnson gmbh milan dsseldorf orthoclinical diagnostic vistakon madrid lifescan gmbh rome sweden neckargemund netherlands janssencilag ortho biotech cordis benelux sollentuna rosellen amersfoort johnson johnson orthoclinical diagnostic gmbh janssencilag sollentuna neckargemund tilburg johnson johnson consumer vistakon johnson johnsongaba products norderstedt almere sollentuna greece johnson johnson medical switzerland janssencilag pharmaceutical saci zaventem cilag athens schaffhausen norway johnson johnson hellas janssencilag greiter athens oslo baar johnson johnson poland janssencilag medical product janssencilag zug athens warsaw janssencilag hungary johnson johnson poland zoo baar janssencilag kft warsaw budapest johnson johnson portugal spreitenbach johnson johnson kft janssencilag farmaceutica ltda budap queluz mcneil consumer nutritional europe zug ireland johnson johnson limitada janssencilag pharmaceutical limited queluz ortho biotech cork baar johnson johnson professional johnson johnson ireland limited products limitada turkey tallaght queluz johnson johnson limited istanbul italy russia cordis spa johnson johnson llc janssencilag milan moscow istanbul asiapacificafrica johnson johnson indonesia saudi arabia jakarta johnson johnson saudi arabia australia riyadh depuy australia pty ltd israel nottinghill victoria biosense europe singapore haifa janssencilag singaporemalaysia janssencilag pty ltd singapore north ryde janssencilag kibbutz shefayim johnson johnson medical singapore johnson johnson medical pty ltd singapore north ryde johnson johnson consumer kibbutz shefayim johnson johnson pte ltd johnson johnson pacific pty limited singapore sydney johnson johnson medical kibbutz shefayim orthoclinical diagnostic tasmanian alkaloid pty limited singapore japan westbury tasmania depuy japan inc south africa china tokyo janssencilag pty ltd johnson johnson china ltd sandton shanghai janssen pharmaceutical tokyo johnson johnson pty limited johnson johnson medical ltd east london shanghai johnson johnson tokyo johnson johnson medical pty ltd shanghai johnson johnson ltd halfway house shanghai johnson johnson medical tokyo taiwan shanghai johnson johnson janssencilag taiwan pharmaceuticals ltd orthoclinical diagnostic taipei shanghai tokyo johnson johnson medical taiwan xianjanssen pharmaceutical ltd vistakon japan taipei beijing tokyo johnson johnson taiwan ltd egypt korea taipei johnson johnson egypt sae janssencilag korea ltd cairo seoul thailand janssencilag pharmaceutica limited hong kong johnson johnson korea ltd bangkok janssencilag seoul hong kong johnson johnson asean limited johnson johnson medical korea ltd bangkok johnson johnson hong kong limited seoul hong kong johnson johnson medical thailand malaysia bangkok johnson johnson medical hong kong johnson johnson sdn bhd hong kong selangor darul ehsan united arab emirates johnson johnson middle east inc morocco vistakon dubai johnson johnson morocco hong kong casablanca india pakistan janssencilag johnson johnson pakistan mumbai private limited johnson johnson limited karachi mumbai philippine janssencilag philippines johnson johnson professional metro manila mumbai indonesia johnson johnson philippines inc janssencilag pharmaceutica metro manila jakarta corporate shareholderinvestor information principal office common stock dividend reinvestmentplan johnson johnson plaza list new york stock exchange plan allow partial new brunswick new jersey stock symbol jnj dividend reinvestment additional monthly cash investment shareholder relation contact year johnson johnson stock annual meeting michael ullmann brokerage commission annual meeting shareholder corporate secretary service charge stock purchase place april hyatt interested join plan regency new brunswick albany investor relation contact need authorization form andor street new brunswick new jersey helen short background information meet convene vice president investor relation equiserve trust company shareholder cordially invite attend formal notice meeting outside proxy statement proxy send shareholder transfer agentand registrar hear impair question stock holding shareholder inquiry regard report available certificate replacementtransfer ing stockrelate matter communi copy company annual dividend address change cate directly equiserve trust report quarterly direct company telecommunication report form security equiserve trust company device tdd telephone number exchange commission box service annual report available online providence rhode island wwwjnjcom shareholders outside charge write request outside secretary company principal world wide web site office call internet equiserve home httpwwwjnjcom outside httpwwwequiservecom follow trademark service mark trade name johnson johnson affiliated company appear report ace acrome act acuvue acuvue acuvue colours day acuvue aqua aveeno babycentercom bandaid benecol velocity cardiovations carefree cidex clean clear codman compeed concerta cordis cypher daktarin definity depuy dermabond ditropan doxil duragesic durogesic durotep ejnj elmiron eprex ergamisol erypo ethicon ethicon endosurgery euroflash floxin global gynecare gynecare intergel gynecare tvt hakim haldol idmicro type system imodium independence ibot independence iglide independence technology induo janssen janssencilag johnson johnson johnsons johnson lactaid lap disc leustatin lifescan mammotome max maxpro mcneil mitek monarch monistat motilium motrin mylanta natusan neutrogena nizoral onetouch oros ortho ortho biotech orthoclinical diagnostic orthoclone okt ortho evra orthomcneil orthonovum ortho tricyclen parentcentercom penaten personal product company pinnacle piz buin positively radiant preservation procrit prolene promogran propulsid purpose razor defense reach remicade reminyl reopro retavase retina micro rhogam risperdal risperdal consta roc joseph shower shower simply cough simply stuffy smartscan splenda sporanox stayfree sterrad stugeron sundown summit surestep surevue surgifoam campaign nursing future topamax tricilest tylenol ultra ultracet ultrasmart uristat viactiv vicryl watchband incision vistakon follow trademark company appear report aciphex pariet eisai ltd levaquin daiichi pharmaceutical natrecor scios inc pepcid merck inc llc annual report print entirety recycle paper johnson johnson credo believe responsibility doctor nurse patient mother father use product service meeting need high quality constantly strive reduce cost order maintain reasonable price customer order service promptly accurately supplier distributor opportunity fair profit responsible employee man woman work world consider individual respect dignity recognize merit sense security job compensation fair adequate working condition clean orderly safe mindful way help employee fulfill family responsibility employee feel free suggestion complaint equal opportunity employment development advancement qualified provide competent management action ethical responsible community live work world community good citizen support good work charity bear fair share taxis encourage civic improvement well health education maintain good order property privileged use protect environment natural resource final responsibility stockholder business sound profit experiment new idea research carry innovative program develop mistake pay new equipment purchase new facility provide new product launch reserve create provide adverse time operate accord principle stockholder realize fair return johnson johnson plaza new brunswick new jersey